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resumo 
 
 
A comunicação celular baseia-se em vias de sinalização, que quando 
desreguladas podem levar ao desenvolvimento de doenças, desde 
cancro a doenças autoimunes. As interações proteína-proteína (PPIs) 
são fundamentais para a regulação de vias de sinalização. Deste modo, 
a identificação e a modulação de PPIs é crucial para entender 
mecanismos pato-fisiológicos de diferentes doenças. O sistema 
reprodutor masculino não é exceção, estando as PPIs no centro da 
manutenção de funções celulares na produção e funcionamento dos 
gâmetas. A PPP1CC2 é uma proteína com expressão enriquecida nos 
testículos e a sua interação com a AKAP4, proteína específica de 
testículo, aparenta ser um bom alvo para novos fármacos. A 
monitorização da modulação da interação PPP1CC2/AKAP4 através do 
sistema de dois-híbrido em mamífero (MTH) é crucial. Os sistemas 
dois-híbrido são técnicas específicas para validar PPIs ex vivo. Desta 
forma, neste trabalho explorou-se o sistema MTH para uma análise de 
potenciais drogas para a modulação de PPIs. Isto permitirá identificar 
um novo alvo terapêutico e/ou desenvolvimento de drogas que afetem 
especificamente uma PPI. Esta metodologia baseia-se no facto de em 
eucariotas, a transcrição de genes ocorrer apenas quando o domínio de 
ligação (BD) e o domínio de ativação (AD) do DNA estão próximos. Ao 
fundir o DNA complementar de duas proteínas que interagem com o BD 
e AD, a expressão de um gene repórter é ativada e a interação 
detetada. O objetivo principal desta tese é implementar o MTH no 
laboratório de transdução de sinal, para identificar e modular PPIs num 
sistema que mimetiza o ambiente onde ocorrem PPIs – células de 
mamíferos. 
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abstract 
 
The base of cell communication is signalling pathways which, when 
deregulated can lead to several diseases, from cancer to autoimmune 
diseases. Protein-protein interactions (PPIs) are the backbone of signalling 
pathways. Consequently, identifying and modulating PPIs can unravel the 
pathophysiological mechanisms of a disease. When considering the male 
reproductive system, the same is observed, hence PPIs are responsible and 
regulate most of the cellular functions. PPP1CC2 is a testis enriched protein, 
key to sperm motility acquisition. Its interaction with AKAP4, also a testis-
specific protein, appears to be a potential new drug target. Therefore, the 
modulation of PPP1CC2/AKAP4 interaction under mammalian two-hybrid 
system is crucial. 
Two-hybrid system, particularly the mammalian two-hybrid (MTH), is an 
efficient technique to validate PPIs ex vivo. Thus, we will explore this tool for 
highthroughput drug screening through the modulation of PPIs. Consequently, 
it will be used to identify either a target to a specific drug or drugs. This 
methodology relies on the fact that in eukaryotes, gene transcription only 
occurs when the DNA-binding domain (BD) and DNA activation domain (AD) of 
a transcription factor come into close proximity. When fusing the cDNA of two 
interacting proteins with the BD and AD, a reporter gene is expressed and the 
interaction can be detected.  
The main goal of this thesis is to implement the MTH into the Signal 
Transduction laboratory and to be able to identify and modulate PPIs in a 
system that can mimic the natural way PPI’s occur – mammalian cells. 
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I. Introduction  
I.1. Male reproductive system – testis and sperm 
In males, gamete (spermatozoa) are produced by spermatogenesis in the testis which are 
housed inside the scrotum (Figure 1.a). The composition of testicular parenchyma is 
highly intricate of seminiferous tubules, where the production of spermatozoa occurs, and 
it is surrounded by the interstitial tissue containing Leydig cells. Leydig cells are 
responsible for testosterone production, which is essential for spermatogenesis. The 
seminiferous epithelium is complemented with sustentacular Sertoli cells and a stratified 
layer of developing male germ cells, as spermatogonia, spermatocytes and spermatids 
(1). Beside the role in the maintenance of the integrity of seminiferous epithelium, Sertoli 
cells have an important role in the regulation of male germ cell proliferation and 
differentiation, as well as in male germ cells nutrition (2). 
Spermatogenesis can be divided into three major phases: proliferation and differentiation 
of spermatogonia; meiosis; and spermiogenesis (Figure 1.b) (3). The spermatogenesis is 
initiated with several cell divisions and differentiation processes of spermatogonia, 
resulting in primary spermatocytes. Then, each spermatocyte formed increases markedly 
in size and undergoes through the first meiotic division (secondary spermatocyte) followed 
by a second meiotic division (spermatid). The final phase of spermatogenesis is the 
differentiation of spermatids into spermatozoa known as spermiogenesis. Spermiogenesis 
involves extensive cell remodelling and results in morphological mature spermatozoa. 
The mammalian spermatozoa consist of a head and a flagellum, Figure 1.c. The head 
comprises a nucleus and an acrosome surrounded by the plasma membrane (4). In the 
nucleus is the condensed chromatin with genetic information, the acrosome is a result 
from Golgi complex suppression and covers two thirds of the anterior head surface (5). 
The flagellum is the longest part of the sperm and is a critical structure for motility, it is 
composed by the axoneme, fibrous sheath (FS) and outer dense fibres (ODF). While the 
axoneme function as the motor of the sperm, the FS and ODF modulate the frequency 
and pattern of flagellar beating. The flagellum is divided into four pieces, the connection of 
head with flagellum (connecting piece), the region with the mitochondrial sheath that 
surrounds the axoneme (mid-piece), the main portion of the tail (principal piece) and the 
end piece (6).  
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I.2. Protein-protein interactions in male fertility 
Protein-protein interactions (PPIs) are one of the most important mechanisms used by 
mammalian cells to regulate a variety of cellular and molecular activities, such as 
transcription, translation, signal transduction and enzyme reaction (7). PPIs are 
dependent on cell type, cell cycle phase, development stage, environmental conditions, 
protein modifications (e.g. phosphorylation), the presence of cofactors, binding partners 
and inhibitors. Modifications and regulation of proteins necessarily involve a transient PPIs 
(8), interactions that quickly bound and unbound, are a key to regulation of protein 
Figure 1 – Diagram of testis and seminiferous tubes. a. Represents a cross section of the testis, revealing 
the seminiferous tube and its distribution in lobules, epididymis head, corpus and tail. b. Shows a section of a 
seminiferous tube, representing several Sertoli cells and the disposition of spermatogonia before the initiation 
of the meiotic division I to became a spermatocyte (2n), and further meiotic division 2 to became a spermatid 
(n) and be able to suffer speciation and became a spermatozoa, present in the seminiferous tube lumen. c. 
Illustrate a spermatozoa cell, with the acrosome cap in the head, the midpiece, where mitochondria are 
agglomerated and the tail evident Figures were produced using Mind the Graph. 
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functions (9). These interactions are common in signalling pathways as they provide a 
mechanism for a fast cellular answer to extracellular factors (10) such as drugs. On other 
hand, stable PPIs are obligatory, with structural or functional roles, this PPIs are related 
with permanent complexes, such as interactions of cytochrome c (11) or some hetero-
oligomeric proteins (12), like subunits of ATPase. 
PPIs can interfere with kinetic properties of proteins; act as a general mechanism to 
tolerate substrate channelling; construct a new binding site for small effector molecules, 
inactivate or suppress the protein activity; and modify the specificity of a protein for its 
substrate through interaction with distinct binding partners (13). Characterization of 
different PPIs might be essential to comprehend diverse cellular functions (8). Over the 
past decades, many PPIs have been identified, both ex vivo, for example by co-
immunoprecipitation, and in vivo, for example by yeast two-hybrid. PPIs have emerged as 
promising drug targets, and the interest in identification and modulation of PPIs has 
grown, since it can unravel the pathophysiological mechanisms of a disease (14–16). On 
a therapeutic perspective, targeting PPIs should result in a better diagnosis of the disease 
and lesser side effects of treatments.  
In mammalian spermatozoa reversible phosphorylation of structural and regulatory 
proteins are involved in intracellular control mechanisms responsible for functional 
modifications, in order to overcome the lack of DNA transcription in spermatozoa (17).  
The spermatozoa released from the testis are morphological mature but immotile and 
unable to fertilize the oocyte (18). To acquire motility, spermatozoa must produce energy 
to fuel the movement, and several signalling pathways must be activated/inhibited to 
initiate movement. Spermatozoa needs high and constant amounts of adenosine 
trisphosphate (ATP) (19). It is believe that oxidative phosphorylation in mitochondria 
and/or glycolysis in the flagellum and head are the metabolic pathways required to provide 
energy to spermatozoa (20–22).  
Most signalling pathways in spermatozoa are related with motility acquirement, 
capacitation and acrosome reaction. Smith and colleagues (23) suggested the important 
role of phosphoprotein phosphatases (PPP) in the regulation of spermatozoa motility 
through the epididymis. The group showed that inhibition of phosphoprotein phosphatase 
1 (PPP1) activity results in the initiation and stimulation of motility. It has been proposed 
that primary regulation of flagellar beating, that happens in the epididymis, occurs through 
reversible phosphorylation of axonemal proteins (24,25). Changes in pH; intracellular 
concentrations of calcium ions; and cyclic adenosine monophosphate (cAMP) biochemical 
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and morphological changes (26) that leads to alterations of protein phosphorylation (27) 
and high concentration of cAMP are believed to stimulate the phosphorylation of sperm 
proteins by protein kinase A (PKA), increasing motility (28). 
After maturation, spermatozoa are stored in the distant part of the caudal epididymis 
where they remain quiescent. Sperm motility is activated during ejaculation when 
spermatozoa are mixed with fluids from accessory glands (29).  
I.2.1. Phosphoprotein phosphatase 1 (PPP1) 
Protein phosphorylation is the process that adds a phosphate group (PO3-) to either 
hydroxyl group of an amino acid of serine, threonine or tyrosine. It is involved in many 
cellular processes and is especially important to stablish protein function by its activation 
or deactivation through modification of enzymes activity, cellular location, or association 
with other proteins. Protein phosphorylation is the most abundant post-translational 
modification in eukaryotic organisms. It is believe that 30% of the proteins encoded by the 
human genome contain covalently bound phosphate, and that abnormal phosphorylation 
can be a cause or a consequence of many human diseases (30). For phosphorylation and 
dephosphorylation are necessary protein kinases and protein phosphatases, respectively. 
This process is not only controlled by the balanced activity of protein kinases and protein 
phosphatases but also by their restricted localisation (30,31).  
Protein kinases (PKs) are involved in transferring of a terminal phosphate group of an 
ATP molecule to a hydroxyl group of an amino acid (serine, threonine or tyrosine, and 
histidine in prokaryotes) side chain of a protein. It can be distinguished by the ability of 
interaction with both aminoacids (Ser/Thr kinase); only with tyrosine (Tyr kinases); or with 
all three amino acids (dual-specificity kinases) (32). PKs can be activated or deactivated 
by (1) phosphorylation, (2) binding of activator proteins or inhibitor proteins or small 
molecules (e.g. regulatory proteins), (3) controlling their location in the cell relative to their 
substrates. Regulatory proteins and domains allow to restrict specificity proteins into a 
particular subcellular compartment and can modulate proteins activity (33). 
Protein phosphatases (PPs) are the primary effectors of dephosphorylation (removal of 
the phosphate group). PPs can be grouped into three main classes based on sequence, 
structure and catalytic function. Those classes are (i) Ser/Thr protein phosphatases 
(STPPs), (ii) Tyr phosphatases and (iii) the dual specific phosphatases that 
dephosphorylate all three residues. The largest class of PPs is the phosphoprotein 
phosphatase (PPP) family comprising PPP1, PPP2A, PPP2B, PPP4, PPP5, PPP6 and 
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PPP7, and the metallo-phosphatase dependent on Mg2+- or Mn2+- (PPPM) family, 
composed primarily of PPP2C. 
PPP1 family has a role on a variety of cellular processes, such as cell division; 
transcription; translation; muscle contraction; glycogen and lipid metabolism; neuronal 
signalling and embryonic development (26). It is estimated to catalyse about a third of 
proteins dephosphorylation reactions in eukaryotic cells. PPP1 does not exist freely within 
the cell, being most of the time associated with another protein (34). In human, the 
catalytic subunit is express from three different PPP1 genes, that give rise to four isoforms 
α/A, β/B, γ1/C1 and γ2/C2 (35). PPP1C isoforms differ in their C- terminal of the amino 
acid sequence, being more than 90% identical in its sequence. PPP1CC1 and PPP1CC2 
isoforms occurs by alternative splicing from the same gene, Ppp1cc (36), as represented 
in Figure 2, and the expression of both isoforms is distinct, PPP1CC1 is ubiquitously 
expressed whereas PPP1CC2 is testis-enriched and sperm-specific (37).  
In constant interaction with PPP1, there is a vast and heterogenous group of proteins, 
called PPP1 interacting-proteins (PIPs), PPP1 regulatory subunits. Depending on the PIP, 
PPP1 isoforms can play different roles in the cell. So far, more than 200 PIPs were 
identified, resulting in the involvement of PPP1 in various functions of the human 
physiology (38). 
 
Figure 2 - Schematic representation of human PPP1CC C-terminals isoforms. PPP1CC1 and PPP1CC2 
differ in the C-terminus sequence (in bold), leading to the specific role of each protein in the cell. These two 
isoforms arise from alternative splicing of the gene sequence correspondent exon of PPP1CC C-terminus. * 
denotes the termination codon. 
PPP1CA and PPP1CB are expressed in most of mammalian tissues except in skeletal 
and heart muscles. Levels of PPP1CC1 are higher in brain, small intestine and lung when 
compared with other tissues, and it is undetectable in heart and spleen. In brain, these 
three PPP1 isoforms were shown to be present in different regions and revealed also 
specific subcellular localization. PPP1CC2 expression is enriched in testis and 
spermatozoa (low expression in brain, lung, spleen and thymus) (39–41). 
In human testis, all four PPP1 isoforms are expressed (42). However, their cellular and 
subcellular distributions are distinct. During mitosis, PPP1CA localizes to the centrosome; 
PPP1CC1 is associated with microtubules of the mitotic spindle; and PPP1CB is strongly 
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associated with chromosomes. These differences on subcellular and cellular distribution 
may be the result of specific interactions of each isoforms and consequently respond to 
distinct signalling complexes (43,44). PPP1CC2 is predominantly localized in post-meiotic 
cells, in the cytoplasm of secondary spermatocytes, round spermatids and elongated 
spermatids (45). In the spermatozoa, this isoform is distributed through the flagellum, 
midpiece, and posterior region of the head (24), suggesting a role in motility and 
acrosome reaction. 
I.2.1.1. PPP1CC2 Interactions 
Most of PIPs have a PP1 docking motif, known as RVxF motif (46). The RVxF binding site 
is a shallow hydrophobic groove on the surface of the PPP1, away from the catalytic site 
(47) and it is essential for the binding of many PIPs (46). The presence of this RVxF motif 
can allow weaker secondary interactions motifs to bind with PPP1, serving as an 
anchoring point (48). The contribution of the RVxF motif to the binding of PPP1 is 
interactor-dependent. Some PIPs still interact strongly with PPP1 in the presence of an 
excess of a synthetic RVxF peptide or despite alterations in their RVxF motif (46). The 
substrates that interact with PPP1 through this binding motif do not lead to an additional 
change on the PPP1 conformation, when compared with PIPs without the RVxF motif to 
bind PPP1 (47). 
Interactions of PPP1CC2-PIPs had a notorious role to understand PPP1CC2 function in 
testis and spermatozoa maturation in the epididymis. The main regulation suggested for 
PPP1CC2 activity during spermatozoa motility acquisition is the presence of inhibitors, 
such as PPP1R2 (inhibitor 2, I2), PPP1R7 (sds22) and PPP1R11 (inhibitor 3, I3), but also 
by protein 14-3-3 and A-kinase anchoring proteins (AKAPs) (38). Moreover, in 2013, 
Korrodi-Gregório et al. identified a new PPP1R2 (inhibitor 2) isoform in human sperm, 
PPP1R2 pseudogene 3 (PPP1R2P3). This isoform has the unique feature of Thr73 being 
replaced by Pro avoiding glycogen-synthase kinase 3 (GSK3) phosphorylation. 
PPP1R2P3 protein binds directly to PPP1CC and the inactive PPP1CC2-inhibitor complex 
formed cannot be activated by GSK-3 phosphorylation. Korrodi-Gregório et al. 
hypothesize that PPP1R2P3 is only present in caudal motile sperm, representing a 
constitutively inhibitor of PPP1, independent of GSK-3 phosphorylation, and therefore 
responsible for the process of spermatozoa motility acquisition along the epididymis 
journey (38,49).  
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Specifically, PPP1CC2 isoform interacts with Spermatogenic zip protein 1 (Spz1), 
identified as a specific binding partner of this PPP1 isoform. The specificity of this binding 
partner was confirmed by the loss of interaction when the unique C-terminus of PPP1CC2 
was excised, as shown by Hrabchak et al. (2004) (50). Spz1 and PPP1CC2 interaction 
may be required for proper regulation of spermatogenesis and fertility in mice, since 
phosphatase assays using recombinant PPP1CC indicate that increasing concentrations 
of Spz1 are able to inhibit PPP1CC2 (50). Endophilin B1t is a testis-specific splice variant 
of endophilin B1 and it was shown to interact specifically with PPP1CC2. Despite the 
presence of a canonical RVxF motif near the N-terminus, Endophilin B1t does not interact 
with others PPP1C isoforms or with PPP1CC2 mutant lacking the unique C-terminus (51). 
The A-kinase anchoring proteins (AKAPs) have been also related to testis and sperm 
function, specifically AKAP3, AKAP4 and AKAP11 (52).  
PPP1CC2/PIP complexes are essential regulatory components in the signalling 
transduction cascades involved in sperm motility acquisition during epidydimal transit. 
Therefore, the study of new PPP1CC2/PIP complexes in testis and sperm are extremely 
important through a physiological and pathological point of view, as well as a potential 
contraceptive target.  
I.2.2. A-kinase anchor proteins (AKAPs) 
AKAPs are a group of structurally diverse proteins, that have the capacity to directly 
anchor pools of enzymes to a subset location to ensure a particular intracellular signalling 
event. AKAPs were originally classified based on their ability to bind the cAMP-dependent 
protein kinase (53). An important role of the AKAPs is the ability to form multi-protein 
complexes that integrate cAMP signalling with other pathways and signalling events 
(54,55). AKAPs can integrate diverse signalling pathways that co-ordinately regulate the 
phosphorylation of specific cellular substrates (56). In this group of proteins 50 AKAPs 
were already identified (57) from which 20 were cloned (58). Several AKAPs are present 
in spermatozoa - AKAP1, AKAP3, AKAP4, AKAP8, AKAP11, WAVE-1 and MAP2 (52), 
and three of them related with PPP1CC2 – AKAP11, AKAP3, AKAP4 (38). Given that 
many AKAPs have been shown to be present in germ cells and localized to compartments 
related to motility where PPP1CC2 is also present they might be iinvolved in motility 
acquisition (59,60). 
A-kinase anchor protein 11 (AKAP11) is present in both testis and spermatozoa. In testis, 
is localized to germ cells and in mature sperm is restricted to the midpiece. Its location in 
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the midpiece is associated with the cytoskeleton (61). The midpiece associated AKAP11 
could serve to anchor PKA and/or PPP1CC2, directly regulating the contractile machinery 
in the sperm axoneme, as shown by membrane permeable peptides that disruption of RII 
subunit interaction with AKAPs, causes the arrest of sperm motility (62). 
AKAP3 is a testis-specific protein found only in the fibrous sheath and localised in 
principal piece of the tail (circumferential ribs) of human sperm (63,64). It is reported to 
participate in protein-protein interactions with the R-subunit of the PKA (63). 
In human, A-kinase anchor protein 4 (AKAP4) is the most abundant protein in the fibrous 
sheath of sperm and its expression is restricted to testis and sperm. Therefore it seems to 
be a PKA-anchoring testis-specific protein (65). It was shown that AKAP4 gene knockout 
mice lacks flagellar movement, exhibiting a significant change in the activity and 
phosphorylation of PPP1CC2. Together, it was inferred that AKAP4 recruits PKA to the 
fibrous sheath and facilitates local phosphorylation to regulate flagellum functions (66) 
(Figure 3). Considering AKAP4 localization it was hypothesised its involvement in the 
regulation of sperm motility. In a AKAP4 knockout male mice, sperm concentration is not 
affected. However, sperm fails to show progressive motility and consequently the mice is 
infertile (65). A variation in the activity and phosphorylation of PPP1CC2 is induced, which 
suggests that AKAP4 is required to regulate the phosphorylation levels of PPP1CC2 in the 
principal piece of the spermatozoa (69). In a study with human patients whom 
spermatozoa have low or none motility a screening was performed to assess the status of 
FS and the axonemal structure. An association between absence or weak AKAP4-
labelling in the flagellum and absence or weak motility of spermatozoa was suggested 
(60).  
cAMP analogues and phosphodiesterase inhibitors increase the motility of mature 
spermatozoa, proposing that elevated cAMP stimulates the phosphorylation of sperm 
proteins by PKA increasing motility (28). Vieira Silva et. al. (2017) characterized the 
PPP1CC2/AKAP4 interaction as a potential target for modulation of spermatozoa motility, 
a decrease of AKAP4 in asthenozoospermic samples when compared with 
normozoospermic samples is shown. These suggest that the PPP1CC2/AKAP4 
interaction has an important role in spermatozoa motility regulation since the loss of 
PPP1CC2/AKAP4 interaction results in immotile spermatozoa (67).  
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Figure 3 – Schematic representation of human AKAP4. The human protein sequence of AKAP4 has 854 
aminoacids (aa) (grey); AKAP4 motifs are represented (▲). In green is highlighted binding motif of PPP1 
(39RKVICF44), and in orange is shown the binding motifs of AKAP4 to PKA-RI and PKA-RII subunits. 
I.3. Modulation of PPP1 interactions 
Modulation of spermatozoa motility has a key role to understand how motility can be 
increased, in a male infertile situation, or decreased as a contraceptive approach. The 
development of novel male contraceptives would be pivotal to replace or adjuvate the 
ones already available, such as condom or vasectomy. PPP1 are involved in the 
regulation of spermatozoa motility in the epididymis, and it was shown that PPP1 activity 
inhibition induces motility (23). Targeting PPP1 complexes has already been shown, and 
natural and chemical compounds can be used in several diseases (68,69).  
Okadaic acid and calyculin A are known PPP1 inhibitors. Inhibition of PPP1 activity by 
these compounds initiates sperm motility in the caput epididymis without requirement for a 
change in cAMP levels (70). Goto et al (2009) shown that inhibition by calyculin A results 
in the enrichment of the phosphorylated status at the activation loop of the PKA catalytic 
subunit in the mouse spermatozoa principal and midpieces (71). Ammosova et al. (2012) 
demonstrated the viability of inhibiting PPP1 phosphatase activity through regulatory site 
targeting, by inhibition of the HIV-1 transcription and replication. The authors employed 
small molecules targeting to the RVxF-binding site of PPP1 and identified a small 
molecule – 1H4 (patent US 20090264463 A1) – that presumably binds to the RVxF motif 
of PPP1. This molecule selectively disrupt the Tat-PPP1 interaction without showing 
cytotoxicity and not affecting other PPP1 holoenzymes (72). 
The interfaces between PPP1 and PIPs represent an excellent target for pharmacological 
intervention. McConnell et al. (2009) have shown two drugs - salubrinal and trichostatin A 
– that modulate PPP1 complexes. Salubrinal is a small molecule that protect the cell from 
the Endoplasmatic Reticulum stress-induced apoptosis and was shown to diminish the 
level of PPP1-GADD34 complex in cells treated with it. Trichostatin A can disrupts the 
interaction between PPP1 and HDAC6 in glioblastoma and prostate cancer cells (73). 
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Disruption of PPIs by peptides is an appealing strategy due to their affinity and specificity. 
Chatterjee et al. (2012) developed a cell-penetrating peptide - PDP3 – that competes with 
PPP1-interacting proteins (PIP) containing RVxF motifs for binding to PPP1 in living cells. 
The blocking of these interactions by PDP3 promoted PPP1 auto-dephosphorylation 
resulting in active PPP1 that dephosphorylate their substrates (74). 
I.4. Two-hybrid System 
Many functions in cells are controlled by PPIs, hence appropriate methodologies have 
been developed. Yeast two-hybrid (YTH) system was established by Fields and Song in 
1989 (75) and it allows the identification of PPIs. When compared to other biochemical 
methods it has a higher sensitivity, since it allows the identification of weak and unspecific 
interactions (44). The YTH system uses the reconstitution of the Gal4 transcription factor 
of the Saccharomyces cerevisiae to identify PPIs. As any other eukaryotic transcription 
factors, Gal4 requires the close proximity between a DNA-binding domain (BD) and an 
activation domain (AD) (75). Both domains carry out their functions independently, but 
only when they are brought together the transcription of the reporter gene occurs. The 
principle of this system lies in the fusion of each domain with a protein of interest, “bait” 
and “prey” (76). If the interaction between bait and prey proteins occurs, the Gal4 
transcription factor reassembles and the transcription of lacZ reporter gene is induced, 
which results in a blue phenotype when in the presence of X-gal substrate (44,75). 
The importance of this technique is reflected on the number of high confidence binary 
interactions identified. Moreover, it is estimated that about 50% of the interactions 
described in PubMed were identified by YTH screening (44,75,77). Specifically, for PPP1, 
most of its interacting proteins were identified and characterized by YTH. Endophilin B1t, 
Spz1, AKAP3 and AKAP11 are examples of PIPs that were identified by this methodology 
(50,51).This method has contributed to understand male fertility through the 
characterization of the human testis PPP1 interactome. Fardilha et al. (24) performed YTH 
screens from a human testes cDNA library, using as baits different PPP1C isoforms 
(PPP1CC1, PPP1CC2 and PPP1CC2-specific C-terminus). They reported the 
identification of 77 different proteins, some of them unique to a particular PPP1. 35 
proteins were found to exclusively bind PPP1CC2-specific C-terminus, which could reflect 
the PPP1CC2 isoform specificity (44). 
Despite the advantages of this method, it also shows limitations such as, (1) high level of 
false positives; (2) need an identification of more than one reporter gene for identification; 
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(3) auto-activation of the reporter gene; (4) use of yeast, that do not mimic the 
environment where the PPIs occurs in mammalian organisms (44,78). In order to 
overcome some of the YTH drawbacks, mammalian two-hybrid system (MTH) was 
developed (78). 
I.4.1. Mammalian two-hybrid System 
In the MTH system, at least three different types of plasmids are necessary to identify 
PPIs, often called “bait,” “prey,” and “reporter.” Similar with YTH system, the bait encodes 
a protein of interest that is fused to the BD, while the prey encodes a target protein that is 
fused to the AD. These plasmids are then co-introduced into appropriate host cells along 
with the reporter vector, as shown in Figure 4. 
The first study of PPIs in mammalian cells was performed by Dang and colleagues in 
1991. Dang et.al system was based on Gal4-BD from the YTH system and VP16-AD 
(from Herpes virus), with chloramphenicol acetyltransferase (CAT) as the reporter gene, 
to analyse the complex formed between leucine zipper transcription factors (79). 
Later, Lou and colleagues (1997) (78) confirmed that interaction of proteins could be 
studied in mammalian cells. They proved the expression of two chimeric proteins from the 
simian virus 40 T antigens and its interactions with mouse p53 antitumor protein by 
expression of CAT gene under the control of five consensus Gal4 binding sites. Since the 
development of the MTH system, new versions have emerged. Those, were focus on 
transient transfection of bait, prey, and reporter vectors (79). For example, interaction 
between the ERa and SRC1 which phosphorylation is PKA-dependent were studied under 
this method with luciferase as a reporter, to understand the resistance to tamoxifen 
observed in half of the recurrences in breast cancer (80). Isselbacher and colleagues 
optimized a new version of the method where a GFP-based reporter and the bait 
construct were stably integrated into the cells’ genome and the prey expression was 
propagated from a stable vector by the use of the EBNA-1/ori-P system, this method 
allows to perform a cDNA library screening using a specific bait (79). Some studies use 
mammalian two-hybrid as a control technique. In 2010, Naz and Dhandapani (86) use this 
method to check for false positives after YTH system. In these case, human ZP3 was 
cloned into YTH vector and used as bait to find reactive proteins in the human testis cDNA 
library. Six specific clones were identified and the interaction was further confirmed by 
MTH system. Recently, there are studies that use M2H systems to detect peptide 
interactions as Leverson et. al. 2015, in which it was identified a small-molecule MCL-1 
inhibitors with sufficient potency to induce clear on-target cellular activity in cancer (87). 
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Molecules as A-1210477, that induces the hallmarks of intrinsic apoptosis and 
demonstrates single agent killing of multiple myeloma, binds MCL-1 with sub-nanomolar 
affinities and confirmed an ability to disrupt endogenous MCL-1–BH3-only protein 
interactions. By using MTH assays, with Gal4-luciferase as a reporter, and a cell imaging 
platform that tracks BCL-2 family interactions in real time, it was found that A-1210477 
could selectively disrupt MCL-1–NOXA and MCL-1–BIM2A complexes in living cells. In 
2010, extensive mammalian two-hybrid assay-based PPI maps were established using 
pairwise analyses of 1,988 human and 1,727 mouse transcription factors, revealing a total 
of 762 and 877 interactions, respectively (83). The availability of large transcription factors 
combinatorial networks in both human and mouse will provide many opportunities to study 
gene regulation, tissue differentiation, and mammalian evolution (80). 
Figure 4 - Mammalian two-hybrid System assay. a. Cloning of the proteins ORF (gene X and Y) of interest 
and transfection of bait and prey, with the DNA-binding domain (BD) and DNA-activation domain (AD), 
respectively and the reporter plasmid. The plasmids are transfected together to evaluate the PPI between 
protein X and Y, control vectors are also transfected to further analyse the interaction. b. Interaction between 
protein X and Y, b.1) reporter gene is expressed when the recognition of upstream activation site (UAS) 
through the BD in protein X occurs and there is an interaction with protein Y, the interactions ensures that BD 
and AD are close and recruits RNA polymerase I (I) to start the reporter transcription. b.2) When Protein X and 
Y do not come in close proximity the transcription of the report gene does not occurs. 
The need to identify PPIs that occur in a specific part of the cells, like with transmembrane 
proteins, lead to adaptation of MTH. Mammalian protein-protein interaction trap (MAPPIT) 
is a YTH variant that exploits the unique properties of the JAK–STAT (Janus kinase/Signal 
Transducer and Activator of Transcription) signalling pathway. Since the PPIs occur in the 
context of an activated receptor, MAPPIT is the method of choice for the analysis of PPIs 
in signal transduction pathways (81,82).  
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When compared with yeast, the MTH system presents key advantages, since it can mimic 
the complex cellular context where the interactions occur in natural circumstances. 
Furthermore, it allows the study of drugs in an interaction of interest. This system is more 
flexible, since it can be applied into different cell lines. MTH is not dependent on the 
expression of an endogenous coactivator since Gal4-coactivator is transfected into the 
cells to identify if the PPI of interest occurs.  
In this assay, the effects of the cell context on transactivation can be determined since 
ligand-dependent Gal4-coactivator–VP-receptor interactions also rely on endogenous 
cofactors for transactivation. MTH is more straightforward, the transfection of the reporter 
vector allows the detections of nuclear and non-nuclear proteins since it is not dependent 
on transcriptions factors from the nucleus, when compared with YTH where hybrid 
proteins may not be expressed stably in yeast or may not efficiently move into the nucleus 
and express the reporter gene, as an example β-galactosidase (83). The use of positive 
controls with subtracts such as secreted alkaline phosphatase (SEAP) and CAT avoids 
the need of cell lysis, and allows a fast and convenient analysis of PPIs in mammalian 
cells. In the perspective of the target proteins, the native physiological context ensures 
proper folding and provides the necessary cofactors and regulatory proteins involved in 
post-translational modifications (e.g. phosphorylation, acetylation or ubiquitination) or 
assisting any conformational alterations that the target proteins need to undergo to allow 
their interaction (84). 
I.4.2. The use of Mammalian two-hybrid in highthroughput drug 
screening 
The highthroughput (HTS) screening is a methodology used for scientific experimentation, 
with importance for fields like biology or chemistry, especially for drug discovery. HTS 
allows to perform a high scale test, like a library of different compounds, and discover 
drugs that inhibit/stabilize PPIs. 
Berg et al. (2002) screened four small-molecules antagonists of c-Myc/Max dimerization-
domain with 7000 compounds by fusion of fluorophores in the c-Myc/Max complex, when 
in close proximity the energy transferred between fluorophores increased, and when the 
complex is inhibited the energy is not transferred, meaning inhibition of the complex (85). 
Sohn et al (2001) identified 11 potential activators of DPC4 out of a library of compounds. 
The screening of the compounds on this tumour-suppressor gene mutated, DPC4 signal 
transduction pathway was tested in a human pancreatic cancer cell line in order to find a 
therapy that could have a rational role in anticancer therapy (86).  
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Combining MTH and HTS allows to evaluate drug effect in a specific PPIs, which is an 
advantage for therapeutic research, since it allows the development of more target 
specific treatments. As the interface of a particular PPI is determined by the combination 
of interacting domains of two proteins, it will probably exhibit a high level of specificity 
when compared to e.g. the catalytic pocket of an enzyme, which is often well conserved 
throughout a whole enzyme class (84). Several HTP screening assays have been used to 
discover inhibitors of protein interactions (87). In 2006, Yen and colleagues (88) used HTS 
to identify small molecules that can serve as inhibitors of ribozyme self-cleavage. The 
group established cell-based assay in which expression of a luciferase reporter is 
controlled by ribozyme sequences, and screened 58,076 compounds for their ability to 
induce the expression of luciferase. Fifteen compounds were able to inhibit ribozyme self-
cleavage, with highlights for toyocamycins and 5-fluorouridine. Pattyn et al (2008) 
performed HTS to modulate the interaction between HIV reverse transcriptase subunits, 
and analyse the small molecules related to that PIPs (89). Shiu and colleagues found 
small-compounds, such as ADS-J1, XTT formazan and tannin acid, as inhibitors of 
trimerization of gp41, an HIV-1 protein involved in cell entrance, by systematic screening 
for interaction inhibition using 96-well plates and luciferase as a reporter (90). Li et. al. 
(2011) screened more than 3,000 compounds identified with the mammalian two-hybrid 
system with luciferase as a reporter gene on the cellular levels of p53. This study was 
looking for compounds with an inhibitory effect in the interaction of MDM2, an E3 ubiquitin 
ligase, to the tumour suppressor p53. It is believed that p53 is activated by inhibition of 
p53-MDM2 interaction, and the effect of nutlin-3, caylin-1 and three hit compounds 
increased (SL-01, 02, and 03) the levels of p53 protein (91). 
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I.5. Aims 
The mammalian two-hybrid system is without a doubt a powerful tool not only to study 
protein-protein interactions but also to evaluate the effect of small molecules and drugs in 
specific protein-protein interactions pairs. Therefore, we believe the MTH is of a great 
utility in a signalling laboratory. Moreover, since sperm relies on protein-protein 
interactions to adapt to different environments, the MTH is particularly important to study 
sperm protein-protein interactions. This work aimed to implement the MTH into the Signal 
Transduction Laboratory. To accomplish this general goal the following aims were 
proposed: 
 Aim 1: To clone PPP1CC2 and AKAP4 ORF into bait and prey MTH system 
vectors; 
 Aim 2: To transfect and express the PPP1CC2 and AKAP4 bait and prey vectors 
into a mammalian cell line.  
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II. Material and methods 
Experimental procedures were performed in the Signal Transduction Laboratory, Institute 
for Research in Biomedicine (iBiMED), University of Aveiro (Aveiro, Portugal). The details 
of the solutions used in this work are stated in the Supplementary data. 
II.1. Amplification and isolation of plasmids DNA from bacteria 
AKAP4 Open Reading Frame (ORF), transcript variant 1, and PPP1CC2 ORF were 
initially cloned into pCMV6-AC-GFP (RG221765, OriGene, Rockville, MD, USA) and into 
pAS2-1, respectively. Mammalian two-hybrid (MTH) system vectors, Matchmaker 
Clontech pM (bait) and pVP16 (prey) plasmids were kindly provided from Dr Folma Buss, 
Cambridge Institute for Medical Research, Cambridge, United Kingdom. Controls of MTH, 
pG5SEAP, pM53, pM3-VP16, pVP16-T and pVP16-C were a kind gift from Dr 
Sharifah Syed Hassan, Monash, Malasya. 
Initially, all vectors were transformed into E. coli XL1-Blue competent cells. One single 
and isolated colony was retrieved and incubated in LB (Luria-Bertani) broth medium 
(ThermoFisher Scientific, Waltham, MA USA), with appropriate antibiotic (Ampicillin), 
overnight (ON) at 37 ºC with vigorous shaking (220 rpm) for further DNA isolation.  
II.1.1. Transformation of Escherichia coli - XL1-Blue competent 
cells 
E. coli XL1-Blue competent cells were thawed on ice, and 0.5 μl DNA was added and 
gently mixed in separate tubes. The cells were incubated on ice for 20 min. Then, the cells 
were incubated at 42 ºC for 45 s (heat shocked) and after cooled down on ice for 2 min. 
Next, 500 μl of LB medium was added and incubated for 45 min at 37 ºC with shaking at 
180 rpm. The cells were then pelleted for 2 min at 1000 rpm and the supernatant 
discarded, the cells were then resuspended in 100 µl of LB medium and spread on 
LB/ampicillin (50 μg/ml) agar plates and incubated at 37 ºC for 16 h, until colonies 
appeared. 
II.1.2. Purification with NucleoBond® Xtra Midi Plus EF 
Plasmid DNA purification was performed using NucleoBond® Xtra Midi Plus EF 
(Machenery-Nagel, Düren, Germany) kit. To prepare a preculture, a single bacterial 
colony was transferred into 3 ml of LB medium with ampicillin (50 µg/μl) and incubate ON 
at 37 ºC and 180 rpm. After the saturated culture was transferred into 200 ml of LB 
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medium containing ampicillin (50 µg/ml) and incubated in the same conditions. The culture 
was transferred into a falcon and centrifuged at 4500 xg for 15 min at 4°C. The 
supernatant was discarded. The bacterial pellet was resuspended in 8 ml of 
Resuspension Buffer RES-EF with RNase A (0.06 µg/µl) and vortexed. Then, 8 ml of 
Lysis Buffer LYS-EF was added to the suspension and mixed gently by inverting 5 times. 
The suspension was incubated at room temperature (RT) for 5 min. After, 8 ml of 
neutralization buffer NEU-EF was added and the mixture left on ice for 5 min. The 
NucleoBond® Xtra Midi column was prepared by adding 15 ml of Equilibration Buffer 
EQU-EF onto the filter and left to empty by gravity. The suspension was inverted 3 times 
to homogenize and loaded onto the column. To the assemble 5 ml of Filter Wash Buffer 
FIL-EF was added and allowed to empty by gravity. The filter was then discarded and the 
column washed with 35 ml of Wash Buffer ENDO-EF, followed by adding 15 ml of Wash 
Buffer WASH-EF. After emptied, the plasmid DNA was eluted to a new 50 ml centrifuge 
tube by adding 5 ml of Elution Buffer ELU-EF. To precipitate the eluted plasmid DNA, 3.5 
ml of RT isopropanol was added to the samples and vortex thoroughly. The precipitate 
was centrifuged at 15000 ×g for 30 min at 4 °C and the supernatant carefully discarded. 2 
ml of endotoxin-free RT 70% ethanol was added to the pellet and gently mixed. The 
suspension was centrifuged at 12000 ×g for 5 min at RT. Ethanol was discarded and the 
pellet left to dry at RT. After, the pellet was resuspended in an appropriate volume of 
endotoxin-free H2O. Plasmids yield was determined by UV spectrophotometry (DS-11 
FX+ Spectrophotometer - DeNovix, Wilmington, DE 19810 SA). 
II.2. Confirmation of Control vectors 
To confirm the size of the vectors, these were submitted to endonuclease restriction. 
Control vectors are based on pM and pVP16 vector; thus NdeI (New England Biolabs, 
Herts, UK) enzyme was chosen, since both vectors sequence present the NdeI restriction 
site. 300ng of each DNA were cut according to manufacturer’s instructions.  
II.3. PPP1CC2 and AKAP4 cloning into MTH vectors 
II.3.1. PPP1CC2 Cloning 
To clone PPP1CC2 ORF into the pM and pVP16 vectors the DNA of interest was 
extracted from the original vectors, pAS2-1-PPP1CC2 (92). 5 μg of pAS2-1-PPP1CC2 
was first cut with SalI (New England Biolabs, Herts, UK) and after gel extraction and 
purification all the eluted DNA was enzyme restricted with SamI (ThermoFisher Scientific, 
Waltham, MA USA). Enzymatic reactions were performed as recommended by the 
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manufacture’s in a volume of 50 μl and incubated ON at 37 ºC (Table 1). MTH vectors, pM 
and pV16, were endonuclease restricted with SalI (New England Biolabs, Herts, UK), and 
were electrophoretic purified from the agarose gel to perform a second endonuclease 
restriction with all the DNA recovered from the gel with SmaI (ThermoFisher Scientific, 
Waltham, MA USA), these reactions were performed under manufactures instructions for 
a volume of 50 µl, at 37 ºC ON. Linearized vectors (pM and pVP16) and PPP1CC2 
fragment were then electrophoretic purified and extracted from the gel. 
Table 1 – Reaction to linearize the bait and prey MTH vectors. 
 pM (μl) pVP16 (μl) 
DNA 1 1.3 
10x Enzyme buffer 5 5 
Enzyme 2 2 
Deionised H2O 42 41.7 
Final volume 50 μl 
II.3.1.1. Electrophoretic purification  
To visualize the DNA fragments an agarose gel electrophoresis was prepared and the 
DNA fragments were separated by molecular size. For a 1% agarose gel, the appropriate 
amount of agarose powder (Invitrogen, LifeTechnologies S.A., Madrid, Spain) was 
dissolved in TAE 1x (Supplementary data 2), and GreenSafe Premium (NZYTech, Lda., 
Lisboa, Portugal) was added as manufacturer’s instructions. The solution was poured into 
the appropriate tray and the comb was placed. The gel was allowed to polymerize for 30 
min. The samples and GeneRuler 1 kb DNA Ladder (ThermoFisher Scientifics, Waltham, 
MA USA) were mixed with 6x loading buffer (ThermoFisher Scientifics, Waltham, MA 
USA). Once the gel was solidified it was placed into the tank field with TAE 1x and the 
comb removed carefully. The samples and the marker were loaded into the wells and run 
at 70 V. When the dye had migrated the appropriate distance, the gel was examined 
under a UV light, using Gel Doc™ XR+ System (Bio-Rad Laboratories, Lda, Almada, 
Portugal) and the bands were cut from the gel. 
II.3.1.2. Plasmid DNA Gel Clean-up 
Extraction of DNA from agarose gel was performed by following the instructions of 
NucleoSpin Gel and PCR Clean-up kit (Machenery-Nagel, Düren, Germany). For each 
100 mg of gel 200 µl of NTI binding buffer was added on a 2 ml tubes, heated at 50°C and 
shacked for 7 min. The result mixture (maximum 700 µl) was loaded to the column and 
centrifuged for 30 s at 11000 xg and the liquid was discarded. This step was repeated until 
all the volume passed through the column. 700 µl of NT3 wash buffer was added and 
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centrifuged for 30 s at 11000 ×g. A second wash of the column was performed in the 
same manner. In order to remove any traces of ethanol, the column was centrifuge for 1 
min at 11000 ×g and the ethanol collected on the bottom discarded. To collect the DNA a 
new tube was used. 20 µl of NE elution buffer was added to the column and incubated at 
RT for 1 min. Finally, DNA was eluted by centrifuging for 1 min at 11000 ×g and stored. 
Plasmids yield was determined by UV spectrophotometry (DS-11 FX+ Spectrophotometer 
- DeNovix, Wilmington, DE 19810 SA). 
II.3.1.3. PPP1CC2 ligation into pM and pVP16 
Linearized PPP1CC2 ORF was inserted into linearized pM and pVP16 by performing a 
1:3 (vector:insert) reaction in the presence of T4 DNA ligase (New England Biolabs, Herts, 
UK) at 16ºC ON, originating pM-PPP1CC2 and pVP16-PPP1CC2 vectors. Controls of 
ligation were performed as described on Table 2. 
The two ligations were transformed into E. coli XL1-Blue competent cells as described in 
section II.1.1. Ten positive colonies were selected, each colony was transferred into 3 ml 
of LB medium with ampicillin (50 µg/µl) and incubate overnight at 37 ºC and 180 rpm. 
Table 2 – Controls performed for pM-PPP1CC2 and pVP16-PPP1CC2 ligation 
 Control 1 Control 2 Control 3 1:3 reaction 
Vector     
Insert  - -  
T4 DNA ligase - -   
 
II.3.1.4. Alkaline lysis “mini prep” 
1.5 ml of bacterial culture from positive clones pM-PPP1CC2 and pVP16-PPP1CC2 were 
transferred into a microtube and centrifuged at 14000 xg for 1 min at 4°C. The 
supernatant was discarded. The bacterial pellet was resuspended in 100 µl of ice-cold 
Resuspension solution through vigorous vortexing. Then, 200 µl of freshly prepared lysis 
solution was added to the microtube and mixed by inverting several times. 150 µl of ice-
cold Neutralization solution were added and the microtube gently inverted 20 times. The 
microtube was then left on ice for 5 min, centrifuged at 14000 xg for 10 min at 4°C and the 
supernatant transferred to a clean microtube. DNA was precipitated by adding 2× the 
volume of absolute ethanol at -20 °C and vortexed. The mix was incubated for 10 min at      
-20 °C. Then, it was centrifuged at 14000 xg for 5 min at 4°C, the supernatant was 
completely removed and the pellet washed with 70% ethanol. After centrifugation, at 
14000 xg for 5 min at 4 °C, the pellet was allowed to air-dry for 10 min. The DNA was 
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dissolved in H2O containing DNAse-free pancreatic RNAse (20 mg/ml). Transformants of 
PPP1CC2 were endonuclease restricted with XhoI and AKAP4 with XhoI. When 
separated by agarose gel electrophoresis, the fragment pattern allowed the identification 
of positive colonies resulting from cloned vectors. The plasmids that generated the 
expected DNA fragments were transformed in XL1-Blue competent cells (described on 
section II.1.1) for a purified extraction by NucleoSpin plasmid and further analysed by 
sequencing. 
II.3.2. AKAP4 Cloning 
In order to clone AKAP4 ORF into MTH vectors In-Fusion Cloning (Clontech, Saint-
Germain-en-Laye, France) kit was used, this kit allows a rapid and efficient cloning of one 
or more fragments of DNA into any vector. The DNA of interest was extracted from the 
original vectors, pCMV6-AKAP4-GFP through PCR. The PCR products were then cleaned 
by the Cloning Enhancer reagent, and the DNA of interest was ligated to the plasmids, pM 
and pVP16 by In-Fusion Cloning Reaction with the same primers used to extract the 
fragment of DNA. 
Both vectors were linearized with SalI (New England Biolabs, Herts, UK) restriction 
endonuclease and purified as descried on section II.3.1. The primers, were designed as 
suggested in the Kit User Manual and the online platform of Clontech to perform the In-
Fusion HD Cloning, sequence can be find on Supplementary table 3. 
II.3.2.1. Extraction and Amplification of ORFs 
AKAP4 ORF was amplified according to manufacturer’s instruction using the CloneAmp™ 
HiFi PCR Premix. This polymerase ensures a high sensitivity, specificity, priming 
efficiency and extension efficiency. To perform the PCR a Master Mix was done with 
concentrations described on Table 3. 
Table 3 – Reaction of AKAP4 ORF amplification 
Reaction component Volume Final concentration 
CloneAmp HiFi PCR Premix 12.5 µl 1X 
Primer 1 5–7.5 pmol 0.2 – 0.3 µM 
Primer 2 5–7.5 pmol 0.2-0.3 µM 
DNA template < 1 ng  
Deionized water Up to 25 μl 
Final volume 25 μl 
The reaction to amplify AKAP4 ORFs from the original plasmids was performed on a 
thermal cycler with the following cycling conditions: 
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AKAP4 PCR      
95 ºC  10 s      
55 ºC  15 s x35 cycles    
75 ºC  13 s      
II.3.2.2. PCR product purification 
To purified PCR product, 2 μl of Cloning Enhancer (CE) were added to 5 μl of the PCR 
product in a new PCR tube. After, was incubated on a ThermoCycler at 37 °C for 15 min, 
then at 80 °C for 15 min. The In-Fusion Cloning Procedure for Cloning Enhancer-Treated 
PCR Fragments was then performed for each plasmid, pM and pVP16, as described on 
Table 4. The reaction occurs at 50 °C for 15 min, it was stored at -20 ºC until 
transformation of competent cells. 
Table 4 – In-Fusion Cloning Reaction 
Reagent Volume for pM vector Volume for pVP16 vector 
5X In-Fusion HD Enzyme Premix 2 μl 2 μl 
Linearized vector 5 μl (75 ng) 5 μl (50 ng) 
Purified PCR fragment 2 μl 2 μl 
Deionized water 1 μl 1 μl 
Final volume 10 μl 10 μl 
II.3.2.3. Transformation of Stellar Competent cells 
Stellar Competent Cells were thaw on ice just before use. After thawing the cells, were 
mix gently to ensure even distribution, and then 50 μl of competent cells were placed into 
a 15 ml round-bottom tube. To each 50 μl of competent cells 2.5 μl of the In-Fusion 
reaction was added. The tubes were incubated on ice for 30 min. The competent cells 
were heat shocked for 45 s at 42 ºC and placed on ice for 2 min. 450 µl of SOC medium 
was added to bring the volume up to 500 µl and incubated for 1h at 37 ºC with shaking 
(180 rpm). After incubation, 20 µl of the cells were pippeted and the volume was brought 
up to 100 µl. Each diluted transformation reaction was spread on a separate LB plate 
containing the appropriate antibiotic for the cloning vector (50 µg/ml of ampicillin). The 
remaining of each transformation reaction was centrifuge at 6000 rpm for 5 min. The 
supernatant was discarded and each pellet was resuspended in 100 μl of fresh SOC 
medium. Every transformation reaction was spread on a separate LB plate containing 
appropriate antibiotic for the cloning vector (50 µg/ml of ampicillin). All plates were 
incubated overnight (~16 h) at 37 ºC. 
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To perform the control, ~200 µg of pM vector, pVP16 vector, pM linearized with SalI and 
pVP16 linearized with SalI were transformed in 16.6 μl of Stellar competent cells, as 
described previously.  
II.3.2.4. Analysis of In-Fusion cloning products 
To identify positive clones, isolated colonies of pM-AKAP4, pVP16-AKAP4, were picked. 
To screen the recombinant plasmid in the transformants, the plasmid DNA was extracted 
from 3 isolated colonies using an alkaline lysis “mini prep” approach as described on 
section II.3.1.4. and digested with the restriction endonuclease. Transformants of AKAP4 
were digested with EcoRI and PvuII. When separated by agarose gel electrophoresis, the 
fragment pattern allowed to identify the positive clones resulting from transformation of the 
bait and prey vectors. The plasmids that generated the expected DNA fragments were 
transformed in E. coli XL1-Blue competent cells for a purified extraction by NucleoSpin 
plasmid and further analysed by sequencing. 
II.4. Amplification and purification of PPP1CC2 and AKAP4 vectors by 
NucleoSpin® Plasmid 
To ensure a proper cloning of PPP1CC2 and AKAP4 with the vectors, sequencing of all 
plasmids was performed. To ensure DNA purity a positive clone was transformed into E. 
coli XL1-Blue competent cells (as described in II.1.1) and DNA was extracted and purified 
using the NucleoSpin Plasmid kit. Briefly, a single bacterial colony was transferred into 3 
ml of LB medium containing ampicillin (50 µg/ml) and incubated overnight at 37 °C with 
vigorous shaking. 1.5 ml of saturated culture was collected into a microtube and 
centrifuged at 11000 xg for 30s. The supernatant was discarded and removed as much as 
possible. The pellet was resuspended in 250 µl of Buffer A1 with RNase A (0.4 µg/µl) by 
vortexing vigorously. 250 µl of Buffer A2 was added to the mix and the tube inverted 8 
times, turning the samples blue. The mix was incubated at RT for 5 min, allowing the lysis 
to occur. After incubation of the lysate 300 µl of Buffer A3 (neutralization) was added and 
mixed thoroughly by inverting until the blue samples became colourless. Lysate was 
centrifuged for 5 min at 11000 ×g to clarify and to remove bacterial debris. The lysate was 
loaded in a NucleoSpin® Plasmid Column in a Collection Tube (2 ml) and centrifuged at 
11000 ×g for 1 min to bind DNA of interest in the silica membrane. The flow-through was 
discarded from the tube. This step was repeated until all the remaining lysate was load. 
The silica membrane was washed with 600 µl of Buffer A4, supplemented with ethanol, 
and centrifuged at 11000 ×g for 1 min. The flow-through was discarded and the column 
centrifuged at 11000 ×g for 2 min to remove ethanol residues from the silica membrane. 
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The DNA was collected into clean microtube, by adding 30 µl of Elution buffer (AE) to the 
membrane and left in incubation for 1 min at RT and centrifuged at 11000 xg for 1 min. 
This step was repeated with 20 µl of Elution buffer (AE) in order to collect as much DNA 
as possible from the membrane. Each extraction of the DNA obtained by In-Fusion 
reaction was then analysed by restriction digestion. Bait and prey vectors fused with 
AKAP4 ORF were digest with restriction enzymes EcoRI and with PvuII, and the vectors 
fused with PPP1CC2 ORF were digest with restriction enzymes XhoI. The mix for each 
sample were done as described below:  
Table 5 – Reactions of constructed plasmids with endonuclease restriction. 
Reagent pM-AKAP4 (μl) pVP16-AKAP4 
(μl) 
pM-PPP1CC2 
(μl) 
pVP16-
PPP1CC2 (μl) 
DNA 1 1 1 1 
10x Enzyme buffer 1 1 1 1 
Enzyme 0.3 0.3 0.3 0.3 
MQ-H2O 7.7 7.7l 7.7 7.7 
Final volume 10 10 10 10 
II.5. Plasmid sequencing 
After confirmation of pM-PPP1CC2, pVP16-PPP1CC2, pM-AKAP4 and pVP16-AKAP4 by 
restriction endonucleases, the samples were analysed by sequencing. pM vector with 
AKAP4 and PPP1CC2 was sequenced with Gal4-BD primer (forward) and with T7 primer 
(reverse). pVP16 vector with AKAP4 and PPP1CC2 were sequenced with Sp6 primer 
(forward) and with T7 primer (reverse). To obtain the full sequence of AKAP4, pM-AKAP4 
and pVP16-AKAP4 vectors were further sequenced using primers that recognized the 
middle of the AKAP4s sequence, primer 5 and 6 on Supplementary table 3. 
II.6. DNA sequence analysis  
Clones with PPP1CC2 and AKAP4 ORF were sent to Eurofins genomics (Ebersberg, 
Germany). The nucleotide sequence obtained from each clone was visualized and 
analysed using Finch TVTM software (http://www.geospiza.com/Products/finchtv.shtml) 
that enables the visualization of chromatograms and a direct BLAST search. 
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II.7. Cell culture 
HeLa cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) 
medium supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics (1% 
penicillin/streptomycin). Cells were grown in 10cm plates in a 5% CO2 humidified 
incubator at 37 ºC and sub cultured every 2-3 days.  
II.7.1. Endogenous AKAP4 expression in HeLa cells 
To identify if AKAP4 was expressed endogenously in HeLa cells, 1×106 cells were plated 
in a 100mm plate and incubated ON in 10 ml of DMEM supplemented with 10% FBS and 
5% penicillin/streptomycin with coverslips on plate’s bottom. The coverslips were then 
collected from the plate and an immunofluorescence protocol was performed. 
II.7.1.1. Immunofluorescence protocol 
Coverslips were collected to 12 wells plate and washed 2 times with 1x PBS. The cells 
were fixed with 4% Para-formaldehyde (PFA), for 20 min at RT. PFA was removed and 
the coverslips wash 3 times with 1x PBS. In order to permeabilize the cells, 2 ml of 0.2% 
of Triton X-100 was added, for 10 min at RT. After, coverslips were washed 3 times with 
1x PBS and unspecific binding places in cells were blocked using 5% bovine serum 
albumin (BSA), 30 min at RT. The cells were treated with 50 µl of primary antibody (AB), 
for 1h at RT, anti-AKAP4 (ab56551) (1:1000), respectively. The AB was washed 3 times 
with 1xPBS and the respective secondary AB (anti-mouse (ab32723), Invitrogen (1:300)) 
was distributed per each coverslip, and incubated for 1h at RT, wrapped in wet paper. 
Negative controls were performed, HeLa cells with no secondary AB, HeLa cells with Anti-
mouse secondary AB. The antibody was washed 3 times with 1xPBS and each coverslip 
was dyed with Hoesch (1:8000) to coloured the cell’s nucleus. To assemble the slides the 
coverslips were dip in dH2O and mounted with Mowiol solution. Slides were analysed and 
pictures obtain on a Motorized inverted system microscope IX81 (Olympus Portugal - 
Opto-Digital Tecnologias, S.A., Lisboa, Portugal) on a 100x objective (oil emerged).  
II.7.2. PPP1CC2 and AKAP4 HeLa transfection  
To identify if the proteins were expressed in HeLa cells, firstly, 1×106 cells were plated in a 
100mm plate and incubated in 10 ml of DMEM supplemented with 10% FBS without 
antibiotics one day before transfections process. Around 70-90% confluent at the time of 
transfection was established. On samples with GFP coverslips were added for microscopy 
analysis. For each transfection, the DNA/lipofectamine complexes were prepared under 
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manufacturer’s instructions. 50 µl of lipofectamine® 2000 were diluted in 1450 µl of Opti-
MEM™ I Reduced Serum Medium (ThermoFisher Scientific, Waltham, MA USA) and 
added to 20 µg of plasmid DNA previously diluted in 1500 µl of the same medium. The 
mixture was allowed to complex for 25 min at RT. Then, 3 ml of the complexes were 
added to the plate drop-by-drop and the plate was mixed gently by rocking it back and 
forth. 24 h after incubation at 37 ºC in a CO2 incubator, the cells were washed twice in 1× 
PBS, coverslips were collected for a 6 well plates and cell extracts were prepared. To 
prepare the extracts, 100 µl of boiled SDS 1% was added to each plate and cells were 
collected with a scrapper. Cells were on constant shack at 4 ºC for 30 min to lysate, lysed 
cells were then centrifuged at 16000 xg for 20 min and the supernatant was collected to a 
new tube. All the controls of transfections were done under the same protocol, such as 
HeLa cells without DNA addition, empty pM vector, empty pVP16 vector, pEGFP-N1 
vector and pCMV6-AKAP4-GFP vector. 
Coverslips with pCMV6-AKAP4-GFP and pEGF-N1 transfections, the cell were fixed with 
4% PFA, as described on section II.7.1.1. 
II.7.3. Bicinchoninic acid assay  
Extracts were mass normalized using the bicinchoninic acid (BCA) assay (Fisher 
Scientific, Loures, Portugal). Samples were prepared by adding 5 µl of each sample plus 
20 µl of 1% SDS in a 96-well plate. Standard protein concentrations were prepared as 
described in Supplementary table 1. Samples and standards were prepared in duplicate. 
The Working Reagent (WR) was prepared by mixing BCA reagent A with BCA reagent B 
in the proportion of 50:1. Then, 200 µl of WR was added to each well (standards and 
samples) and the plate was incubated at 37ºC for 30 min. Once the 96-well cooled to RT 
the absorbance was measured at 562 nm using an Infinite® 200 PRO (Tecan, 
Switzerland). A standard curve was obtained by plotting BSA standard absorbance vs 
BSA concentration, and used to determine the total protein concentration of each sample. 
II.7.4. Western Blotting  
The protein extracts of HeLa cells were resolved by 10% SDS-polyacrylamide gel 
electrophoresis (PAGE) and proteins were electrotransferred onto nitrocellulose 
membranes. The gel was run at 200 V and transferred at 200 mA for 2 h. Non-specific 
protein-binding sites on the membrane were blocked for 1h with 5% BSA in Tris-buffered 
saline containing 0,1% Tween 20 (TBS-T) or 5% Milk in TBS-T, for AKAP4 and PPP1CC2 
blots, respectively.  
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The membranes for endogenous and transfected PPP1CC2 and AKAP4 were then 
washed with TBS-T and incubated with primary antibodies rabbit anti-PPP1CC2 (G502) 
and rabbit anti-AKAP4(ab123415) overnight at 4 ºC. After the incubation, the membranes 
were washed three times with TBS-T for 10 min each and incubated with the appropriate 
secondary antibody for 1h at RT, infrared IRDye®680RD anti-rabbit (926-68071) 
secondary antibodies (1:5000) from LI-COR Biosciences (Lincon, NE, USA). Blots were 
washed three times for 10 min with TBS-T and once with Tris-buffered saline (TBS: 25 
mM Tris-HCl, pH 7.4, 150 mM NaCl) and immunodetected using the Odyssey Infrared 
Imaging System (LI-COR® Biosciences, US). As a control for protein charge in the wells, 
the membranes were incubated with mouse anti-β-tubulin (32-2600) (1:2000), 40 min at 
RT. After the incubation, the membranes were washed three times with TBS-T for 10 min 
each and incubated with the appropriate secondary antibody for 1 h at RT, 
IRDye®800CW anti-mouse (926-32210) secondary antibody (1:5000) from LI-
CORBiosciences (Lincon, NE, USA) and immunodetected using the Odyssey Infrared 
Imaging System (LI-COR® Biosciences, US). 
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III. Results 
The work performed aimed to implement the MTH into the Signal Transduction 
Laboratory. To accomplish such goal, MTH control vectors were prepared for transfection 
and PPP1CC2 and AKAP4 were cloned into MTH vectors. Two methodologies were used. 
PPP1CC2 plasmids construction was performed under a “traditional” cloning protocol. For 
AKAP4 plasmids construction In-Fusion HD Cloning Plus CE was used. Finally, 
assessment of endogenous and transfected PPP1CC2 and AKAP4 expression on 
mammalian cell lines was performed. The next section presents a detailed description of 
the results. 
III.1. MTH control vectors are correct 
Since MTH control vectors were a gift, sent on paper, we ensured the purity of plasmids 
after isolation and extraction from E. coli XL1-Blue competent cells. DNAs were 
endonuclease restricted with NdeI, since the restriction site for this enzyme is expected to 
be present in all MTH plasmids (no vector map available). 
 
After restricted with NdeI, pM3-VP16 presents one band at 4.4 kb, pM-53 at 4.6 kb, 
pVP16-T at 4.0 kb and at 1.3 kb (total 5.5 kb), pVP16-CP at 4.5 kb and pG5SEAP 
presents two bands, at 3.0 kb and 1.5 kb (total 4.5 kb). Therefore, patterns observed in 
Figure 5 revealed that the vectors are correct and well amplified since the bands were as 
expected. Therefore, the MTH control vectors can be further used in MTH assay. 
Figure 5 – Endonuclease restriction of MTH control vectors. It shows the patterns of all the control 
vectors for the MTH system undigested (first lane of each plasmid) and digested with NdeI endonuclease 
(second lane of each plasmid). Marker – GeneRuler 1kb ThermoFisher. 
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III.2. PPP1CC2 plasmids construction 
To validate and characterize the PPP1CC2/AKAP4 interaction by MTH, PPP1CC2 ORF 
was extracted from pAS2-1-PPP1CC2 (previously generated in our lab) by digestion with 
SmaI/SalI and directionally subcloned into SmaI/SalI-digested pM and pVP16 vectors. 
The resulting plasmid was sequenced to check for mutations and confirm proper cloning 
(fusion protein in the correct reading frame). 
III.2.1. PPP1CC2 was successfully cloned into pM and pVP16 vectors 
pM and pVP16 vectors, as well as, pAS2-1-PPP1CC2 vector suffered a sequential 
endonuclease restriction, firstly with SalI. It was then electrophoretic purified and 
extracted. After, DNAs had a second endonuclease restriction with SmaI, resulting in the 
linearized vectors and PPP1CC2 fragment, as shown in Figure 6. After that, DNA was 
extracted from the gel. 
 
Figure 6 - Purified pM and pVP16 vectors and pAS2-1 restricted with SmaI/SalI. The figure shows the 
purified vectors (pM and pVP16) and the PPP1CC2 fragment (lower fragment in pAS2-1-PPP1CC2 (~1.1 kb)) 
for extraction. Marker – GeneRuler 1kb ThermoFisher. 
After extraction, PPP1CC2 fragment was cloned into the vectors, pM and pVP16, by T4 
DNA ligase reaction. The resulting vectors were transformed into XL1-Blue competent 
cells and isolated colonies were selected to incubate and extract DNA to confirm positive 
clones by endonuclease restriction with XhoI. It was expected for pM-PPP1CC2 to digest 
into two fragments of 3.2 kb and 1.3 kb; and for pVP16-PPP1CC2 was expected that the 
vector became linearized with 4.2kb of size.  
Figure 7.a. shows positive clones for pM-PPP1CC2 and figure 6.b. shows a positive clone 
for pVP16-PPP1CC2. pVP16-PPP1CC2 clone 2 appears to be a negative clone, it 
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presents the same pattern as the empty pVP16 vector, which indicate that PPP1CC2 was 
not cloned into the plasmid. Positive clones were then sent for sequencing to confirm the 
correct reading frame of the inserts. 
a.                       b. 
 
III.2.2.  pM-PPP1CC2 and pVP16-PPP1CC2 are in frame with Gal4-BD 
and VP16-AD 
To check the sequence of the plasmids pM-PPP1CC2 and pVP16-PPP1CC2 cloned with 
SmaI/SalI DNAs were sequenced. This allowed to confirm that PPP1CC2 ORF was 
correctly inserted into the plasmids and in the correct reading frame, Figure 8.  
Note that, this PPP1CC2 sequence results from fusion of human PPP1CC1 with the C-
terminus of rat PPP1CC2 (92). There is a non-translated part of the sequence in 
PPP1CC2 sequence (green). When compared with the human C-terminus the sequence 
has one alteration, an alanine (A) is replaced by a glycine (G, orange arrow in Figure 8).  
 
Figure 7 – Positive clones 
of pM-PPP1CC2 and 
pVP16-PPP1CC2.  
a. pM-PPP1CC2 
enzymatic restriciton with 
XhoI. pM-PPP1CC2 clones 
digested with XhoI. b. 
pVP16-PPP1CC2 
enzymatic restriciton with 
XhoI. pVP16-PPP1CC2 
clones digested with XhoI. 
Marker - GeneRuler 1kb 
ThermoFisher. 
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Figure 8 - Partial sequence of PPP1CC2 in pM and pVP16 vectors. The sequence of PPP1CC2 extracted 
from pAS2-1 vector (in blue) after SmaI/SalI restriction (underlined in blue and in green, respectively) and its 
introduction into pM and pVP16 vectors. The non-translated PPP1CC sequence is in green. Methionine codon 
of PPP1CC2 reading frame is in pink and stop codon in red (*). 
III.3. AKAP4 plasmid construction 
Similarly to PPP1CC2, AKAP4 ORF was cloned into the appropriate vectors however, a 
different cloning method was used. Consequently, the DNA of human AKAP4 was 
extracted from pCMV6-AKAP4-GFP with a PCR reaction and cloned into pM and pVP16 
linearized vectors through In-Fusion Cloning reaction. The resulting plasmids were 
sequenced to check for mutations and confirm proper cloning (fusion protein in the proper 
reading frame). 
III.3.1. AKAP4 was successfully cloned into pM and pVP16 vectors 
pM and pVP16 vectors were endonuclease restricted with SalI, becoming linearized. They 
were then electrophoretic purified and extracted, Figure 9. AKAP4 ORF was amplified 
from the original vector with primer 1 and 2 (Supplementary table 3), Figure 10 confirmed 
that AKAP4 ORF amplification went as expected, resulting in a DNA fragment with 2.6 kb. 
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III.3.2. AKAP4 cloned into pM and pVP16 
To obtain single plasmids, the DNA was first transformed into bacteria Stellar Competent 
Cells, provided with In-Fusion kit and analysed by restriction digestion. Plasmids with the 
AKAP4 insert were restricted with EcoRI and PvuII endonucleases, it was expected for 
pM-AKAP4 to result into two fragments of 5.7 kb and 369 bp for PvuII digestion and 4.6 kb 
and 1.4 kb with EcoRI digestion. For pVP16-AKAP4 was expected two fragments of 5.5 
kb and 369 bp for PvuII digestion and 4.4 kb and 1.4 kb for EcoRI digestion. 
In Figure 11.a and 11.b, show positive clones for pM-AKAP4 plasmid when cut with PvuII 
and positive clones for restriction of EcoRI. These patterns prove the cloning of AKAP4 
into pM. Figure 11.c and 11.d show positive clones for pVP16-AKAP4 endonuclease 
restricted with the same enzymes, while pVP16-AKAP4 clone 2 DNA may result from a 
false positive. 
Figure 9 – MTH linearized vectors with SalI.  
Marker - GeneRuler 1kb ThermoFisher., First 
lane of each plasmid in uncatted and the 
second lane shows the linearized plasmid, pM 
linearized (~3.5 kb) and pVP16 linearized (~3.3 
kb).  
Figure 10 – AKAP4 PCR amplification. 
AKAP4 was extracted and amplified by a PCR 
reaction, AKAP4 PCR product resulted from 
CloneAmp Hi-Fi reaction. Marker – GeneRuler 
1kb ThermoFisher,  
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III.3.3. pM-AKAP4 and pVP16-AKAP4 are in frame with Gal4-
BD and VP16-AD 
To check the successfully cloning of AKAP4 into pM and pVP16, pM-AKAP4 and pV16-
AKAP4 were sequenced. Figure 12 shows that AKAP4 ORF was cloned into the MTH 
vectors. It allowed to confirm that AKAP4 ORF was successfully cloned into both vectors 
in the correct reading frame, Figure 12. 
Figure 11 - Fragment pattern produced by endonuclease digestion of In-Fusion products. 
Marker – GeneRuler 1kb ThermoFisher. a. pM-AKAP4 enzymatic digestion with PvuII. b. pM-AKAP4 
enzymatic digestion with EcoRI. c. pVP16-AKAP4 enzymatic digestion with PvuII. d. pVP16-AKAP4 
enzymatic digestion with EcoRI. 
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Figure 12 - Partial sequence of AKAP4 in pM and pVP16 vectors. The sequence of AKAP4 extracted by 
PCR reaction with primer 1 and 2 from pMCV6-AKAP4-GFP vector is in blue and its correct introduction into 
pM and pVP16 vectors. Methionine codon of PPP1CC2 reading frame is in pink and stop codon in red (*). 
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III.4. AKAP4 is expressed in HeLa cells and presents cytoplasmic 
distribution 
To evaluate the presence and determine the subcellular location of endogenous AKAP4, 
immunofluorescence studies were performed in HeLa cells, with mouse anti-AKAP4 and 
respective secondary AB. HeLa cells are expected to express AKAP4 endogenously since 
it is a carcinoma cell line and AKAP4 has been identified as a cancer/testis (CT) antigen. 
Figure 13 shows the images captured after immunofluorescence for AKAP4. It is possible 
to see that AKAP4 is endogenously expressed in this cell line, and appears to have a 
cytoplasmic and plasma membrane localization.  
 
Figure 13 – Endogenous AKAP4 expression in HeLa cells. a. Shows the cell nucleus stained with Hoechst 
33258 (blue), the AKAP4 was probed with mouse anti-AKAP4 (primary AB) and anti-mouse (green) 
(secondary AB), the third column shows the merged pictures. b. The control for the secondary AB, the nucleus 
cells are dyed in blue and the secondary antibody does not present unspecific ligations.  
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To identify AKAP4 subcellular location when overexpressed, AKAP4 fused with a GFP 
(pCMV6-AKAP4-GFP) was transfected into HeLa cells. In Figure 14 is possible to observe 
that AKAP4-GFP is localized throughout the entire cell, suggesting a cytoplasmic 
subcellular localization.  
 
Figure 14 – Transfection of AKAP4 fused with GFP into HeLa cells. a. Shows the control for GFP, with 
pEGFP-N1 transfected, and the nucleus cell dyed with Hoechst 33258. b. Shows the transfection of pCMV6-
AKAP4-GFP in HeLa cells. 
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III.5. Gal4BD-PPP1CC2 pVP16AD-PPP1CC2, Gal4BD-AKAP4 and 
pVP16AD-AKAP4 are expressed in HeLa cells 
To check if PPP1CC2 and AKAP4 cloned into pM and pVP16 vectors are expressed in 
HeLa cells, pM-AKAP4, pVP16-AKAP4, pM-PPP1CC2 and pVP16-PPP1CC2 were 
transfected into HeLa cells. To identify expression of PPP1CC2 and AKAP4 by HeLa cells 
the extracts were run in a 10% SDS-PAGE gel. Blots were incubated ON with primary 
antibody, Anti-PPP1CC2 (1:5000) and Anti-AKAP4 (1:5000) and the immunoblot with 
Mouse anti-β-tubulin (1:2000) to confirm that all the protein loaded in the wells of each blot 
were in identical quantities, Figure 15. 
Endogenous PPP1CC2 if expressed in HeLa cells should have a molecular weight of 
approximately 39 kDa, while when fused with Gal4-BD or VP16-AD, should present a 
molecular weight of 61 kDa and 53 kDa, respectively. Endogenous AKAP4 if expressed in 
HeLa cells should have a molecular weight of approximately 94 kDa, while when fused 
with Gal4-BD and VP16-AD, should present a higher molecular weight. On pM-AKAP4 the 
expressed protein has attached the BD from Gal4-BD, appearing around 117 kDa and on 
pVP16-AKAP4 the protein has attached the AD from VP16-AD, revealing the protein 
expression on 109 kDa. In Figure 15.a. is possible to observe that HeLa cells do not 
express endogenous PPP1CC2. However, when transfected, PPP1CC2 is expressed as 
a hybrid protein with Gal4-BD or VP16-AD. In Figure 15.c. is possible to observe that 
endogenous AKAP4 is expressed in this cell line, as well as when transfected AKAP4 is 
expressed as a hybrid protein with Gal4-BD or VP16-AD. Therefore pM-PPP1CC2 and 
pVP16-PPP1CC2 can be used in MTH. 
 
 
 
 
 
 
 
                     a. 
 
                     b. 
 
                     c. 
 
                     d. 
 
Figure 15 – PPP1CC2 and AKAP expression in HeLa Cells. Marker – NZYColour Protein Marker II 
(Nzytec, Lisboa, Portugal), a. PPP1CC2 immunodetected using an anti-PPP1CC2 (G502, homemade 
(1:5000)). c. AKAP4 immunodetected using an anti-AKAP4. b. and d. Tubulin immunodetected using anti-β-
tubulin ((1:2000) (32-2600) Invitrogen). 
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IV. Discussion 
The goal of these work was to construct the molecular tools to study the interaction 
between PPP1CC2 and AKAP4 using the mammalian two-hybrid system and implement 
this system in the Signal Transduction Laboratory.  
Identifying PPIs has a key role to understand signalling pathways responsible for all 
cellular process and the molecular mechanism behind many diseases. Currently, many 
techniques are available to identify PPIs, from co-immunoprecipitation to yeast two-hybrid 
system. The mammalian two-hybrid is able to mimic the complex cellular context where 
the interactions occur in natural circumstances. It is more flexible, since it can be applied 
into different cell lines, allowing studies on a specific tissue. Moreover, the identification of 
PPIs is not dependent on the expression of an endogenous coactivator, as in YTH 
systems, since it is transfected into the cells. This allows to detect PPIs that have a 
nuclear as well as a non-nuclear cellular localization. The fact that MTH system requires 
co-transfection of at least 3 vectors can be a limitation. Different transfection efficiency 
between vectors can lead to false negatives. On a pharmacologic and therapeutic view, 
this system can be more advantageous for results extrapolations on human proteins roles 
and interactions, as well as, protein modulation. 
To successfully implement the MTH into the Signal Transduction Laboratory, first it was 
necessary to construct the MTH bait and prey plasmids with PPP1CC2 and AKAP4 ORFs. 
These tools must be generated in order to study others PPIs. PPP1CC2/AKAP4 
interaction was chosen to implement the MTH in the laboratory, since this interaction 
appears to be related with motility acquisition and regulation of flagellum functions (66). 
Some studies have suggested that AKAP4 is necessary to regulate the phosphorylation 
levels of PPP1CC2 in the principal piece of spermatozoa (70). Modulating the interaction 
of these proteins might be important to understand and clarify sperm motility acquirement 
and function. Two approaches were undertaken to construct the plasmids of MTH system, 
traditional cloning method and commercial available fast cloning kit (In-Fusion HD Cloning 
Plus CE, 638919, Clontech). PPP1CC2 plasmids were constructed under a “traditional” 
cloning method, where restriction enzymes are used to linearized the vectors and extract 
PPP1CC2 ORF from a pre-existing plasmid. This is a time-consuming method, that 
requires electrophilic purification and extraction taking several days until the DNA is 
suitable for ligation. Besides, restriction ligations are constricted by sequence limitations 
when choosing the endonuclease cutting site and all the variabilities that can interfere with 
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the endonuclease performance. In other hand, In-Fusion cloning kit, the method used to 
construct AKAP4 plasmids, can amplify the sequence of interest without adding additional 
information into the sequence of interest. This kit is a fast and directional way to clone any 
DNA fragment into a plasmid, recommended for long fragments or the fusion of more than 
one fragment, that sometimes under traditional cloning is challenging. The use of primers 
is required to amplify and ligate the DNA into the vectors, purification of fragments is done 
directly into the PCR product. One of the drawbacks of the In-Fusion Cloning method is 
correlated with the primers. Primers for this protocol can get up to 40 nucleotides of 
length, which can induce a low amplification rate of the insert because the melting 
temperatures (Tm) have to be precisely calculated, the percentage of GC ratio has to be 
consider and the possibility of dimers formations in a long primer is higher. On the other 
hand, the major advantage of the In-Fusion Cloning when compared to traditional is the 
duration of the protocol. When compared with T4 DNA ligation, that can take up to 16h to 
ligate the DNA into the backbone, In-Fusion Cloning reaction only takes 15 min and is 
highly efficient. Therefore, the procedure can be done within a day and then the DNA is 
ready to transform into competent cells. The kit is more expensive, which can be a 
disadvantage to use to generate a reduce number of plasmids. 
PPP1CC2 is testis enriched proteins, so their expression in HeLa cells would not be 
expected. Indeed, in Hela cells PPP1CC2 is not endogenously expressed (Figure 14), 
being that it is only expressed when transfected. Some of the other 3 isoforms of PPP1C 
are known to be expressed in HeLa cells. On the other hand, AKAP4, also a testis 
enriched protein, is shown to be express endogenously on HeLa cells (Figure 16). 
Cancer/testis (CT) antigens are a category of tumour antigens with normal expression 
restricted to male germ cells in the testis but not in adult somatic tissues (93). AKAP4 was 
identified as a cancer/testis antigens, and this protein is expressed in cancer cells, such 
as cervical cancer(94), multiple myeloma(95), breast cancer (96), prostate cancer (97) or 
on ovaries carcinoma (98). Siani et al (2013) determined the expression and subcellular 
localization of AKAP4 in four cervical cancer cells (HeLa, C-33A, CaSki and SiHa). It was 
detected in the cytoplasm, plasma membrane, endoplasmic reticulum, Golgi complex and 
mitochondria, but not in the nuclear envelop. Therefore, HeLa cells, as a cervical 
carcinoma cell line, expresses AKAP4 endogenously as shown by Western blot (Figure 
15) and immunofluorescence (Figure 13). We also observed that AKAP4-GFP tag, when 
transfected into HeLa cells appears to have an effect on nucleus conformation, since it 
presents a lobulated structure. Further studies to assess the effect of AKAP4 
overexpression on cell physiology are necessary  
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V. Conclusions and future perspectives 
The goal of these work was accomplished, molecular tools to study the interaction 
between PPP1CC2 and AKAP4 to identify with mammalian two-hybrid system and 
implement this system in the signal transduction laboratory is now possible. All the vectors 
are cloned and ready to use, cell lines are stablished fortransfection of MTH vectors and 
to perform the MTH assay. The bait and prey DNAs were inserted into the MTH vectors 
on the right direction and reading frame. Two different methods were used for construction 
of PPP1CC2 and AKAP4 plasmids.  
The focus of this work was to implement the mammalian two-hybrid system to confirm the 
PPI between PPP1CC2 and AKAP4 in a more physiological system, closer to 
spermatozoa. Moreover, the system in place will be pivotal to identify possible compounds 
that can interfere and modulate that interaction through a highthroughput drug screening. 
Future work should focus upon the optimization of triple transfection of vectors into HeLa 
cells, to perform the MTH system. Several transfection protocols can be tested, to enable 
a faster and more efficient transfection than the recommended on MTH manual (Calcium 
phosphatase protocol). Determination of subcellular location of PPP1CC2 and AKAP4 
when cloned into MTH vectors is important, since the hybrid plasmid would be targeted to 
the nucleus by the SV40 nuclear localization signal (AD – pVP16) and/or by the GAL4 
nuclear localization sequence (BD – pM) for the transcription to occur. The activation and 
binding domain need to be in close proximity, for the transcription to occur. SEAP reporter 
gene, which is downstream and under control of GAL4-responsive element, will be 
activated when the interaction of the two proteins (PPP1CC2 and AKAP4) happens. To 
measure the interaction between these two proteins the us of Great Escape SEAP 
Chemiluminescence protocol will be necessary. On a therapeutic approach, it would be 
interesting to establish this protocol to perform a highthroughput drug screening and 
modulate this protein interaction, since it is proved by our lab to have a role on sperm 
motility when the interaction is inhibited. 
 
  
 
 
VI. References 
43 
 
VI. References 
1.  Kerr JB. Ultrastructure of the seminiferous epithelium and intertubular tissue of the 
human testis. J Electron Microsc Tech. 1991;19(2):215–40.  
2.  Johnson L, Thompson DL, Varner DD. Role of Sertoli cell number and function on 
regulation of spermatogenesis. Anim Reprod Sci. 2008;105(1–2):23–51.  
3.  Yoshida S, Sukeno M, Nabeshima Y -i. A Vasculature-Associated Niche for 
Undifferentiated Spermatogonia in the Mouse Testis. Science (80- ). 
2007;317(5845):1722–6.  
4.  Fawcett DW. The anatomy of the mammalian spermatozoon with particular 
reference to the guinea pig. Zeitschrift fur Zellforsch und Mikroskopische Anat. 
Springer-Verlag; 1965;67(3):279–96.  
5.  Moreno RD, Ramalho-Santos J, Sutovsky P, Chan EK, Schatten G. Vesicular traffic 
and golgi apparatus dynamics during mammalian spermatogenesis: implications for 
acrosome architecture. Biol Reprod. 2000;63(1):89–98.  
6.  Fardilha M, Vieira Silva J, Conde M. Reprodução Humana Masculina: Princípios 
fundamentais (Portuguese Edition). 1st editio. ARC Publishing, editor. 2015.  
7.  He R, Li X. Mammalian two-hybrid assay for detecting protein-protein interactions in 
vivo. Methods Mol Biol. 2008;439:327–37.  
8.  Fiebitz A, Vanhecke D. High-throughput mammalian two-hybrid screening for 
protein-protein interactions using transfected cell arrays (CAPPIA). Methods Mol 
Biol. 2011;723:165–83.  
9.  Perkins JR, Diboun I, Dessailly BH, Lees JG, Orengo C. Transient Protein-Protein 
Interactions: Structural, Functional, and Network Properties. Structure. 2010 
Oct;18(10):1233–43.  
10.  Nyfeler B, Michnick SW, Hauri H-P. Capturing protein interactions in the secretory 
pathway of living cells. Proc Natl Acad Sci. 2005;102(18):6350–5.  
11.  Qin K, Sethi PR, Lambert NA. Abundance and stability of complexes containing 
inactive G protein-coupled receptors and G proteins. FASEB J. 2008;22(8):2920–7.  
12.  Jones S, Thornton JM. Review Principles of protein-protein interactions. 
1996;93:13–20.  
VI. References 
44 
 
13.  Phizicky EM, Fields S. Protein-protein interactions: methods for detection and 
analysis. Microbiol Rev. 1995;59(1):94–123.  
14.  Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, Venkitaraman AR, et al. 
Using a fragment-based approach to target protein-protein interactions. 
Chembiochem. 2013;14(3):332–42.  
15.  Skwarczynska M, Ottmann C. Protein–protein interactions as drug targets. Future 
Med Chem. 2015;7(16):2195–219.  
16.  Bakail M, Ochsenbein F. Targeting protein–protein interactions, a wide open field 
for drug design. Comptes Rendus Chim. 2016;19(1–2):19–27.  
17.  Reid AT, Redgrove K, Aitken RJ, Nixon B. Cellular mechanisms regulating sperm-
zona pellucida interaction. Asian J Androl. Medknow Publications; 2011;13(1):88–
96.  
18.  Florman HM, Ducibella T. Fertilization in Mammals. In: Knobil and Neill’s 
Physiology of Reproduction. 2005. p. 55–62.  
19.  Miki K. Energy metabolism and sperm function. Soc Reprod Fertil Suppl. 
2007;65:309–25.  
20.  Ferramosca A, Provenzano SP, Coppola L, Zara V. Mitochondrial respiratory 
efficiency is positively correlated with human sperm motility. Urology. Elsevier Inc.; 
2012;79(4):809–14.  
21.  Piomboni P, Focarelli R, Stendardi A, Ferramosca A, Zara V. The role of 
mitochondria in energy production for human sperm motility. International Journal of 
Andrology. 2012. p. 109–24.  
22.  Ford WCL. Glycolysis and sperm motility: does a spoonful of sugar help the 
flagellum go round? Hum Reprod Update. Oxford University Press; 
2006;12(3):269–74.  
23.  Smith GD, Wolf DP, Trautman KC, Da Cruz E Silva EF, Greengard P, 
Vijayaraghavan S. Primate Sperm Contain Protein Phosphatase 1, a Biochemical 
Mediator of Motility’. Biol Reprod. 1996;54:719–27.  
24.  Fardilha M, Esteves SLC, Korrodi-Gregório L, Vintém AP, Domingues SC, Rebelo 
S, et al. Identification of the human testis protein phosphatase 1 interactome. 
Biochem Pharmacol. 2011;82(10):1403–15.  
VI. References 
45 
 
25.  Publicover S, Harper C V., Barratt C. [Ca2+]i signalling in sperm — making the 
most of what you’ve got. Nat Cell Biol. 2007;9(3):235–42.  
26.  Chakrabarti R, Cheng L, Puri P, Soler D, Vijayaraghavan S. Protein phosphatase 
PP1γ2 in sperm morphogenesis and epididymal initiation of sperm motility. Asian J 
Androl. 2007;9(4):445–52.  
27.  Vadnais ML, Aghajanian HK, Lin A, Gerton GL. Signaling in Sperm: Toward a 
Molecular Understanding of the Acquisition of Sperm Motility in the Mouse 
Epididymis1. Biol Reprod. 2013;89(5):127.  
28.  Burton KA, Treash-Osio B, Muller CH, Dunphy EL, McKnight GS. Deletion of type 
IIalpha regulatory subunit delocalizes protein kinase A in mouse sperm without 
affecting motility or fertilization. J Biol Chem. American Society for Biochemistry 
and Molecular Biology; 1999;274(34):24131–6.  
29.  Vicens A, Lüke L, Roldan ERS. Proteins involved in motility and sperm-egg 
interaction evolve more rapidly in mouse spermatozoa. PLoS One. Public Library of 
Science; 2014;9(3):e91302.  
30.  Cohen P. The origins of protein phosphorylation. Nat Cell Biol. 2002;4.  
31.  Vlastaridis P, Kyriakidou P, Chaliotis A, Van de Peer Y, Oliver SG, Amoutzias GD. 
Estimating the total number of phosphoproteins and phosphorylation sites in 
eukaryotic proteomes. Gigascience. 2017;6(2):1–11.  
32.  Dhanasekaran N, Reddy EP. Signaling by dual specificity kinases. Oncogene. 
1998;17(11):1447–55.  
33.  Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, 
and functions in cell growth. Physiol Rev. 1993;73(4).  
34.  Felgueiras J. Phosphoprotein phosphatase 1-interacting proteins as therapeutic 
targets in prostate cancer. World J Pharmacol. 2014;3(4):120.  
35.  Gibbons JA, Kozubowski L, Tatchell K, Shenolikar S. Expression of human protein 
phosphatase-1 in Saccharomyces cerevisiae highlights the role of phosphatase 
isoforms in regulating eukaryotic functions. J Biol Chem. 2007;282(30):21838–47.  
36.  Okano K, Heng H, Trevisanato S, Tyers M, Varmuza S. Genomic Organization and 
Functional Analysis of the Murine Protein Phosphatase 1c γ (Ppp1cc) Gene. 
Genomics. 1997;45(1):211–5.  
VI. References 
46 
 
37.  Fardilha M, Esteves SLC, Korrodi-Gregório L, da Cruz e Silva O a B, da Cruz e 
Silva FF. The physiological relevance of protein phosphatase 1 and its interacting 
proteins to health and disease. Curr Med Chem. 2010;17(33):3996–4017.  
38.  Fardilha M, Esteves SLC, Korrodi-Gregório L, Pelech S, da Cruz e Silva OAB, da 
Cruz e Silva E. Protein phosphatase 1 complexes modulate sperm motility and 
present novel targets for male infertility. Molecular Human Reproduction. 2011. p. 
466–77.  
39.  Takizawa N, Mizuno Y, Ito Y, Kikuchi K. Tissue distribution of isoforms of type-1 
protein phosphatase PP1 in mouse tissues and its diabetic alterations. J Biochem. 
1994;116(2):411–5.  
40.  da Cruz e Silva EF, Fox C a, Ouimet CC, Gustafson E, Watson SJ, Greengard P. 
Differential expression of protein phosphatase 1 isoforms in mammalian brain. J 
Neurosci. 1995;15(5):3375–89.  
41.  Trinkle-Mulcahy L, Sleeman JE, Lamond  a I. Dynamic targeting of protein 
phosphatase 1 within the nuclei of living mammalian cells. J Cell Sci. 
2001;114:4219–28.  
42.  Shima H, Hatano Y, Chun YS, Sugimura T, Zhang Z, Lee EY, et al. Identification of 
PP1 catalytic subunit isotypes PP1 gamma 1, PP1 delta and PP1 alpha in various 
rat tissues. Biochem Biophys Res Commun. 1993;192(3):1289–96.  
43.  Andreassen PR, Lacroix FB, Villa-Moruzzi E, Margolis RL. Differential subcellular 
localization of protein phosphatase-1 α, γ1, and δ isoforms during both interphase 
and mitosis in mammalian cells. J Cell Biol. 1998;141(5):1207–15.  
44.  Silva JV, Freitas MJ, Felgueiras J, Fardilha M. The power of the yeast two-hybrid 
system in the identification of novel drug targets: building and modulating PPP1 
interactomes. Expert Rev Proteomics. 2015;12(2):147–58.  
45.  Sinha N, Puri P, Nairn AC, Vijayaraghavan S. Selective ablation of Ppp1cc gene in 
testicular germ cells causes oligo-teratozoospermia and infertility in mice. Biol 
Reprod. 2013;89(5):128.  
46.  Bollen M. Combinatorial control of protein phosphatase-1. Trends Biochem Sci. 
2001;26(7):426–31.  
47.  Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D. Structural 
basis for the recognition of regulatory subunits by the catalytic subunit of protein 
VI. References 
47 
 
phosphatase 1. EMBO J. 1997;16(8):1876–87.  
48.  Hendrickx A, Beullens M, Ceulemans H, Den Abt T, Van Eynde A, Nicolaescu E, et 
al. Docking Motif-Guided Mapping of the Interactome of Protein Phosphatase-1. 
Chem Biol. 2009;16(4):365–71.  
49.  Korrodi-Gregório L, Ferreira M, Vintém AP, Wu W, Muller T, Marcus K, et al. 
Identification and characterization of two distinct PPP1R2 isoforms in human 
spermatozoa. BMC Cell Biol. 2013;14(1):15.  
50.  Hrabchak C, Varmuza S. Identification of the Spermatogenic Zip Protein Spz1 as a 
Putative Protein Phosphatase-1 (PP1) Regulatory Protein That Specifically Binds 
the PP1c 2 Splice Variant in Mouse Testis. J Biol Chem. 2004;279(35):37079–86.  
51.  Hrabchak C, Henderson H, Varmuza S. A Testis Specific Isoform of Endophilin B1, 
Endophilin B1t, Interacts Specifically with Protein Phosphatase-1cγ2 in Mouse 
Testis and Is Abnormally Expressed in PP1cγ Null Mice. Biochemistry. 
2007;46(15):4635–44.  
52.  Carr DW, Newell AEH. The role of A-kinase anchoring proteins (AKaps) in 
regulating sperm function. Soc Reprod Fertil Suppl. 2007;63:135–41.  
53.  Carr DW, Hausken ZE, Fraser IDC, Stofko-Hahn RE, Scott JD. Association of the 
type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein: 
Cloning and characterization of the RII-binding domain. J Biol Chem. 
1992;267(19):13376–82.  
54.  Smith FD, Langeberg LK, Scott JD. The where’s and when’s of kinase anchoring. 
Trends Biochem Sci. 2006;31(6):316–23.  
55.  Jarnæss E, Taskén K. Spatiotemporal control of cAMP signalling processes by 
anchored signalling complexes. Biochem Soc Trans. 2007;35(5):931–7.  
56.  Colledge M, Scott JD. AKAPs: From structure to function. Trends in Cell Biology. 
1999. p. 216–21.  
57.  Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. Nat 
Rev Mol Cell Biol. 2004;5(12):959–70.  
58.  Schwartz JH. The many dimensions of cAMP signaling. Proc Natl Acad Sci U S A. 
National Academy of Sciences; 2001;98(24):13482–4.  
59.  Inaba K. Molecular architecture of the sperm flagella: molecules for motility and 
VI. References 
48 
 
signaling. Zoolog Sci. 2003;20(9):1043–56.  
60.  Moretti E, Scapigliati G, Pascarelli NA, Baccetti B, Collodel G. Localization of 
AKAP4 and tubulin proteins in sperm with reduced motility. Asian J AndrolAsian J 
Androl. 2007;9(9):641–9.  
61.  Reinton N, Collas P, Haugen TB, Skålhegg BS, Hansson V, Jahnsen T, et al. 
Localization of a Novel Human A-Kinase-Anchoring Protein, hAKAP220, during 
Spermatogenesis. Dev Biol. 2000;223(1):194–204.  
62.  Vijayaraghavan S, Goueli SA, Davey MP, Carr DW. Protein Kinase A-anchoring 
Inhibitor Peptides Arrest Mammalian Sperm Motility*. 1997;  
63.  Lea IA, Widgren EE, O’Rand MG. Association of sperm protein 17 with A-kinase 
anchoring protein 3 in flagella. Reprod Biol Endocrinol. 2004;2(1):57.  
64.  Brown PR, Miki K, Harper DB, Eddy EM. A-Kinase Anchoring Protein 4 Binding 
Proteins in the Fibrous Sheath of the Sperm Flagellum. Biol Reprod. 
2003;68(6):2241–8.  
65.  Miki K, Willis WD, Brown PR, Goulding EH, Fulcher KD, Eddy EM. Targeted 
disruption of the Akap4 gene causes defects in sperm flagellum and motility. 2002 
Aug;248(2):331–42.  
66.  Michel JJC, Scott JD. Akap mediated signal transduction. Annu Rev Pharmacol 
Toxicol. 2002;42(1):235–57.  
67.  Vieira Silva J, Yoon S, De Bock P-J, Goltsev A V, Gevaert K, Fernando J, et al. 
Construction and analysis of a human testis/sperm-enriched interaction network: 
Unraveling the PPP1CC2 interactome. 2017;  
68.  Cheng A, Dean NM, Honkanen RE. Serine/threonine protein phosphatase type 
1gamma1 is required for the completion of cytokinesis in human A549 lung 
carcinoma cells. J Biol Chem. American Society for Biochemistry and Molecular 
Biology; 2000;275(3):1846–54.  
69.  Deng L, Dong J, Wang W. Exploiting Protein Phosphatase Inhibitors Based on 
Cantharidin Analogues for Cancer Drug Discovery. Mini Reviews in Medicinal 
Chemistry. 2013. p. 1166–76.  
70.  Fardilha M, Ferreira M, Pelech S, Vieira S, Rebelo S, Korrodi-Gregorio L, et al. 
“Omics” of human sperm: profiling protein phosphatases. OMICS. 2013;17(9):460–
72.  
VI. References 
49 
 
71.  Goto N, Harayama H. Calyculin A-sensitive protein phosphatases are involved in 
maintenance of progressive movement in mouse spermatozoa in vitro by 
suppression of autophosphorylation of protein kinase A. J Reprod Dev. 
2009;55(3):327–34.  
72.  Ammosova T, Platonov M, Yedavalli VRK, Obukhov Y, Gordeuk VR, Jeang KT, et 
al. Small molecules targeted to a non-catalytic “RVxF” binding site of protein 
phosphatase-1 inhibit HIV-1. PLoS One. 2012;7(6).  
73.  McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for 
drug development. Mol Pharmacol. American Society for Pharmacology and 
Experimental Therapeutics; 2009;75(6):1249–61.  
74.  Chatterjee J, Beullens M, Sukackaite R, Qian J, Lesage B, Hart DJ, et al. 
Development of a peptide that selectively activates protein phosphatase-1 in living 
cells. Angew Chemie - Int Ed. 2012;51(40):10054–9.  
75.  Fields S, Song O. A novel genetic system to detect protein-protein interactions. 
Nature. Nature Publishing Group; 1989 Jul 20;340(6230):245–6.  
76.  Stynen B, Tournu H, Tavernier J, Van Dijck P. Diversity in Genetic In Vivo Methods 
for Protein-Protein Interaction Studies: from the Yeast Two-Hybrid System to the 
Mammalian Split- Luciferase System. MMBR. 2012;76:331–82.  
77.  Rezwan M, Auerbach D. Yeast “N”-hybrid systems for protein–protein and drug–
protein interaction discovery. Methods. 2012;57(4):423–9.  
78.  Luo Y, Batalao A, Zhou H, Zhu L. Mammalian two-hybrid system: A complementary 
approach to the yeast two- hybrid system. Biotechniques. 1997;22(2):350–2.  
79.  Dang C V, Barrett J, Villa-Garcia M, Resar LM, Kato GJ, Fearon ER. Intracellular 
leucine zipper interactions suggest c-Myc hetero-oligomerization. Mol Cell Biol. 
1991;11(2):954–62.  
80.  Ravasi T, Suzuki H, Cannistraci CV, Katayama S, Bajic VB, Tan K, et al. An Atlas 
of Combinatorial Transcriptional Regulation in Mouse and Man. Cell. 
2010;140(5):744–52.  
81.  Ulrichts P, Tavernier J. MAPPIT analysis of early Toll-like receptor signalling 
events. Immunol Lett. 2008 Mar;116(2):141–8.  
82.  Eyckerman S, Verhee A, der Heyden J Van, Lemmens I, Ostade X Van, 
Vandekerckhove J, et al. Design and application of a cytokine-receptor-based 
VI. References 
50 
 
interaction trap. Nat Cell Biol. Nature Publishing Group; 2001;3(12):1114–9.  
83.  Mendonça DB, Mendonça G, Cooper LF. Mammalian two-hybrid assays for studies 
of interaction of p300 with transcription factors. Methods Mol Biol. NIH Public 
Access; 2013;977:323–38.  
84.  Lievens S, Caligiuri M, Kley N, Tavernier J. The use of mammalian two-hybrid 
technologies for high-throughput drug screening. Methods. 2012;58(4):335–42.  
85.  Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. 
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced 
transformation of chicken embryo fibroblasts. Proc Natl Acad Sci. 2002 
Mar;99(6):3830–5.  
86.  Sohn TA, Su GH, Ryu B, Yeo CJ, Kern SE. High-throughput drug screening of the 
DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann Surg. 
Lippincott, Williams, and Wilkins; 2001;233(5):696–703.  
87.  Colas P. High-throughput screening assays to discover small-molecule inhibitors of 
protein interactions. Curr Drug Discov Technol. 2008;5(3):190–9.  
88.  Yen L, Magnier M, Weissleder R, Stockwell BR, Mulligan RC. Identification of 
inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput 
screening of chemical libraries. RNA. Cold Spring Harbor Laboratory Press; 
2006;12(5):797–806.  
89.  Pattyn E, Lavens D, Van der Heyden J, Verhee A, Lievens S, Lemmens I, et al. 
MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV 
reverse transcriptase dimerization in intact human cells. J Virol Methods. 
2008;153(1):7–15.  
90.  Shui X, Lu X, Gao Y, Liu C, Ren F, Jiang Q, et al. A mammalian two-hybrid system-
based assay for small-molecular HIV fusion inhibitors targeting gp41. Antiviral Res. 
2011;90(1):54–63.  
91.  Li J, Zhang S, Gao L, Chen Y, Xie X. A Cell-Based High-Throughput Assay for the 
Screening of Small-Molecule Inhibitors of p53–MDM2 Interaction. J Biomol Screen. 
2011;16(4):450–6.  
92.  Browne GJ, Fardilha M, Oxenham SK, Wu W, Helps NR, da Cruz E Silva O a B, et 
al. SARP, a new alternatively spliced protein phosphatase 1 and DNA interacting 
protein. Biochem J. 2007;402(1):187–96.  
VI. References 
51 
 
93.  Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an 
expanding family of targets for cancer immunotherapy. Immunol Rev. 
2002;188(3):22–32.  
94.  Agarwal S, Saini S, Parashar D, Verma A, Jagadish N, Batra A, et al. Expression 
and humoral response of A-kinase anchor protein 4 in cervical cancer. Int J 
Gynecol Cancer. 2013;23(4):650–8.  
95.  Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, et al. AKAP‐4: 
a novel cancer testis antigen for multiple myeloma. Br J Haematol 140, 464–474. 
2008;140(4):465–8.  
96.  Saini S, Jagadish N, Gupta A, Bhatnagar A, Suri A. A Novel Cancer Testis Antigen, 
A-Kinase Anchor Protein 4 (AKAP4) Is a Potential Biomarker for Breast Cancer. 
PLoS One. 2013;8(2).  
97.  Chiriva-Internati M, Yu Y, Mirandola L, D’Cunha N, Hardwicke F, Cannon MJ, et al. 
Identification of AKAP-4 as a new cancer/testis antigen for detection and 
immunotherapy of prostate cancer. Prostate. 2012;72(1):12–23.  
98.  Agarwal S, Saini S, Parashar D, Verma A, Sinha A, Jagadish N, et al. The novel 
cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for 
immunotherapy of ovarian serous carcinoma. Oncoimmunology. 2013;2(5):e24270.  
  
 
Supplementary data 
53 
 
Supplementary data  
Culture Media and Solutions 
1. Bacteria Media 
LB (Luria-Bertani) Broth medium (ThermoFisher Scientific, Waltham, MA USA) with 
Ampicillin (50 μg/μl) 
In 950 ml of deionised water add:  
LB broth 25 g 
Agar 15 g (for plates only) 
Shake until the solutes have dissolved. Adjust the volume of the solution to 1 liter with 
deionized H2O. Sterilize by autoclaving. Add ampicillin (Sigma-Aldrich Química, S.A., 
Sintra) to a final concentration of 50 μg/ml after LB cool down to ≈ 60 ºC. 
2. Agarose Gel  
50x TAE buffer      1x TAE buffer 
To 950 ml of denoised H2O add: 
242 g Tris Base      20 ml of 50x TAE buffer 
7.1 ml Glacial acetic acid    Deionized water up to 980 ml. 
100 ml 0.5 M EDTA (Ph 8.0) 
3. Alkaline lysis solutions  
Resuspension Solution 
50 mM Glucose 
25 mM Tris-HCl (pH 8.0) (NZYTech Portugal, Lisboa, Portugal) 
10 mM EDTA (Sigma--‐Aldrich Química, S.A., Sintra) 
Lysis Solution  
0.2N NaOH  
1% SDS (Amresco, Ohio, USA) 
Neutralization Solution 
3 M Potassium acetate (Sigma--‐Aldrich Química, S.A., Sintra)  
2 M Glacial acetic acid (Sigma--‐Aldrich Química, S.A., Sintra) 
 
Supplementary table 1 - Standards for BCA assay 
Standards BSA (µl) 1% SDS (µl) Protein (µg) 
P0 - 25 0 
P1 0.5 24.5 1 
P2 1 24 2 
P3 2.5 22.5 5 
P4 5 20 10 
P5 10 15 20 
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Supplementary table 2 - Solutions for Western blot 
Running gel 10% (2 gels, 1.5 mm 
thickness) 
ddH2O 
Tris 1.5 M pH8.8 
Acrylamide 40% 
Bisacrylamide 2% 
SDS 10% 
APS 10% 
TEMED 
7.720 ml 
5.000 ml 
4.920 ml 
1.960 ml 
0.200 ml 
0.100 ml 
0.020 ml 
Stacking gel 4% (2 gels, 1.5 mm 
thickness) 
ddH2O 
Tris 0.5 M pH6.8 
Acrylamide 40% 
Bisacrylamide 2% 
SDS 10% 
APS 10% 
TEMED 
4.736 ml 
2.000 ml 
0.784 ml 
0.320 ml 
0.080 ml 
0.040 ml 
0.008 ml 
Tris-HCl 1.5 M pH 8.8 buffer For 1 L dissolve 181.5 g Tris in 800 ml deionized water. 
Adjust pH at 8.8 with HCl and make up to 1 L with 
deionized water. 
Tris-HCl 0.5 M pH 6.8 buffer For 1 L dissolve 60 g Tris in 800 ml deionized water. Adjust 
pH at 6.8 with HCl and make up to 1 L with deionized 
water. 
10% APS (ammonium persulfate) For 10 ml of deionized water add 1 g of APS. 
10% SDS (sodium dodecilsulfate) For 500 ml of deionized water dissolve 50 g of SDS. 
4X Loading gel buffer For 10 ml add 44 ml glycerol, 250 µl Tris-HCl 0.5  M pH 6.8 
buffer, 0.8 g SDS, 0.2 ml β-mercaptoethanol and 3.3 ml 
deionized water. Add bromophenol blue (a small amount). 
Keep it at RT for short periods or at 4ºC for longer periods.  
Tris-Gly 10X Stock For 1 L dissolve 30.30 g Tris (250 mM) and 144.10 g Gly 
(1.92 M) in 1 L of deionized water.  
Running buffer 1X For 1 L add 800 ml deionized water, 100 ml Tris-Gly 10X 
and 10 ml 10%SDS. Make up to 1 L with deionized water. 
Transfer buffer 1X For 1 L add 100 ml Tris-Gly 10X to 700 ml of deionized 
water and 200 ml methanol.  
10X TBS Stock (Tris buffered 
saline) 
For 0.5 L dissolve 6.055g Tris in deionized water and 
adjust pH at 8.0. Add 43.8325 g NaCl and make up to 500 
ml with deionized water.  
1X TBST (TBS + Tween 20) For 1 L add 100 ml TBS 10X and 500 µl Tween-20 to 900 
ml of deionized water. 
5% BSA in TBST 1X For 100 ml of solution dissolve 5 g of BSA in TBST 1X. 
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Supplementary table 3- Primers used to extract interest cDNA’s from original vectors 
and insertion of cDNA’s in the M2H plasmids (pM and pVP16) and sequencing of positive 
clones. 
Name Sequence Sense  
Primer 1 CCGGGGATCCGTCGAATGATGGCGTACTCTGATACTACAATGAT Fw AKAP4 
Primer 2 CTGCAGACGCGTCGACCTACAGGTTAGCGAGCAGC Rv AKAP4 
Primer 5 GTGGAGACAAACAGATGTCCC Fw  pM-AKAP4 
Primer 6 CCCTCAACCTCTACCTG Fw pVP16-AKAP4 
Gal4-BD TCATCGGAAGAGAGTA Fw - 
SP6 CATTTAGGTGACACTATA FW pVP16 
T7 TAATACGACTCACTATAGG Fw - 
*ATG – start codon; Bolt – stop codon; Fw- forward; Rv- Reverse 
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Supplementary figure 1 - pVP16 map (Clontech, Saint Germain en Laye, France). 
pVP16 was used to generate a fusion protein of VP16-AD and AKAP4 or PPP1CC2. The 
hybrid protein is targeted to the cell’s nucleus by the SV40 nuclear localization sequence. 
Transcription is initiated from the constitutive SV40 early promoter (PSV40e); transcription 
is terminated at the SV40 poly A transcription termination signal. Adapted from 
Matchmaker Mammalian Assay Kit 2 User Manual from Clontech.  
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Supplementary figure 2 - pM map (Clontech, Saint Germain en Laye, France). pM 
was used to generate a fusion protein of Gal4-BD and AKAP4 or PPP1CC2. The hybrid 
protein is targeted to the cell’s nucleus by the Gal4 nuclear localization sequence. 
Transcription is initiated from the constitutive SV40 early promoter (P SV40e); 
transcription is terminated at the SV40 poly A transcription termination signal. Adapted 
from Matchmaker Mammalian Assay Kit 2 User Manual from Clontech. 
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Supplementary figure 3 - pG5SEAP map Reporter Vector. pG5SEAP contains five 
consensus Gal4 binding sites (UASG 17-mer (x 5)) and an adenovirus E1b minimal 
promoter upstream of the secreted alkaline phosphatase (SEAP) gene. The DNA-BD 
portion of a hybrid protein expressed from a pM-derived plasmid localizes to the Gal4 
binding sites in pG5SEAP. If the hybrid test protein X interacts with test protein Y 
(expressed as a hybrid protein from a pVP16-derived plasmid), the SEAP gene will be 
transcribed. Adapted from Matchmaker Mammalian Assay Kit 2 User Manual from 
Clontech. 
